Medullary Thyroid Cancer (MTC)

Recent articles related to MTC

Published: Aug 20th, 2021 10:08 AM

Sun Pharmaceutical Industries Limit, MSN Laboratories Pvt Ltd, Shanghai Hope Chem

"Medullary Thyroid Cancer Treatment Second Line Treatment for Renal Cell Carcinoma. Regions and Countries. The Middle East and Africa (GCC Countries and ..."

Published: Aug 20th, 2021 3:06 AM

Could a Burnsville man's ride change a life? That's his hope | Star Tribune

"Thomas Drayton, who has Stage 4C medullary thyroid cancer, has decided to do a benefit ride of one (himself) from the Canadian border to Iowa to raise money for ..."

Published: Aug 19th, 2021 1:13 AM

Selpercatinib-Enhanced Radioiodine Uptake in RET-Rearranged Thyroid Cancer - Docwire News

"Selpercatinib a highly selective RET inhibitor, was recently approved by the FDA for the treatment of RET fusion-positive lung and thyroid cancers."

Published: Aug 18th, 2021 7:03 PM

Konduri Discusses Treating Patients With RET-Mutated NSCLC - Targeted Oncology

"In other words, the preferred medicines are selpercatinib and pralsetinib followed by chemotherapy after progression. What data support the use of selpercatinib ..."

Published: Aug 17th, 2021 7:48 PM

Neuroendocrine Tumors Market Size will Grow Profitably in the Near Future -

"Neuroendocrine tumor arises from cells that produce hormones; thus, ... pheochromocytomas, medullary thyroid cancer, neuroendocrine carcinoma, ..."

Published: Aug 16th, 2021 6:17 PM

Turning Point Therapeutics Initiates TRIDENT-2 Clinical Study Investigating Repotrectinib ...

"... which is being studied in a Phase 1 trial of patients with advanced or metastatic solid tumors harboring genetic alterations in MET; TPX-0046, ..."

Published: Aug 12th, 2021 5:09 AM

Parathyroid Hormone Market 2021 Outlook, Demand, Regional Analysis, Industry Value Chain ...

"... Analysis, Industry Value Chain | Operating Vendors: Pfizer, Cell Genesys Inc, Natpara, Abbott Laboratories, Eli Lilly, Merck, Paladin Labs "

Published: Aug 12th, 2021 1:13 AM

FDA Approval Decision Pending on Cabozantinib as a New Treatment Option for RR-DTC

"The agent is FDA approved for the treatment of multiple advanced solid tumors including for the treatment of metastatic medullary thyroid cancer."

Published: Aug 8th, 2021 7:01 PM

Roundtable Discussion: Perez Explores Therapeutic Options in RET-Mutated NSCLC

"Selpercatinib [Retevmo] seems to have more preference, pralsetinib [Gavreto] came second, and then vandetanib [Caprelsa] was third. How do you ..."

Published: Aug 8th, 2021 1:23 PM

Family spends 4000 a month to keep daughter, 3, alive after brain cancer diagnosis

"Aria's most expensive treatment is ONC201 - a new cancer drug from Germany, which she has been on for five weeks. "It was invented for adults with ..."

Published: Aug 8th, 2021 12:07 AM

Selpercatinib Shows Promise as Valuable Treatment Option for Patients With RET-Mutated Thyroid ...

"Ultimately, the FDA approved pralsetinib for RET-altered thyroid cancer, and it happened in December. There is some tumor lysis that has been ..."

Published: Aug 6th, 2021 9:41 PM

Exelixis (EXEL) Beats on Q2 Earnings & Revenues, Ups Sales View

"Cometriq (cabozantinib capsules) for the treatment of medullary thyroid cancer generated $8.6 million in net product revenues. Exelixis earned $24.9 ..."

Published: Aug 6th, 2021 3:41 PM

Thyroid Cancer Drugs Global Markets Report 2021: Ipilimumab, Cabozantinib-S-Malate, Caprelsa ...

"For example, Vandetanib (Caprelsa) and Cabozantinib (Cometriq) are targeted therapies used to treat advanced medullary thyroid cancer (MTC)."

Published: Aug 6th, 2021 2:56 PM

What Causes Hot Flashes Other Than Menopause?

"An overactive thyroid gland (hyperthyroidism) is when your body produces too ... Other tumors, such as pancreatic tumors, medullary thyroid cancer, ..."

Published: Aug 6th, 2021 3:07 AM

Harper Analyzes Data for Therapies in RET-Mutated NSCLC

"[They also enrolled] patients with nonmedullary thyroid cancer as well as medullary thyroid cancer. We'll discuss the primary end point of response ..."

Published: Aug 5th, 2021 5:10 PM

Exelixis Announces US FDA Accepts for Priority Review the Supplemental New Drug Application ...

"While cancerous thyroid tumors include differentiated, medullary and anaplastic forms, differentiated thyroid tumors make up about 90 percent of cases.¹ ..."

Published: Aug 5th, 2021 3:52 PM

Chimerix Reports Second Quarter 2021 Financial Results and Provides Operational Update

"Blinded Independent Central Review (BICR) of ONC201 Registration Cohort in Recurrent H3 K27M-mutant Glioma Expected in Fourth Quarter 2021 ."

Published: Aug 5th, 2021 2:33 PM

A phase I/II study of rovalpituzumab tesirine in delta-like 3-expressing advanced solid tumors

"... neuroendocrine prostate cancer, and other NEC/NET) and 99 with other solid tumors (melanoma, medullary thyroid cancer [MTC], glioblastoma, and ..."

Published: Aug 3rd, 2021 5:11 AM

CStone announces positive registrational study of the first-in-class drug ivosidenib in Chinese ...

"It is a rapidly progressing disease with a high incidence in the elderly. ... with metastatic RET-mutant medullary thyroid cancer and RET fusion-positive ..."

Published: Aug 1st, 2021 7:03 PM

Rabinowits Discusses Treatment Options in Medullary Thyroid Cancer

"... Medical Oncology at Miami Cancer Institute, Baptist Health South Florida, discussed the case of a 58-year-old patient with medullary thyroid cancer."

Published: Aug 1st, 2021 6:41 PM

Thyroid cancer: Signs and symptoms to look out for, treatment methods

"The common types of thyroid cancer include anaplastic thyroid carcinoma, follicular carcinoma, papillary carcinoma, and medullary thyroid carcinoma."

Published: Jul 30th, 2021 10:25 PM

New Strategies for RET Inhibition May Expand Their Role in NSCLC

"The trial is comparing selpercatinib (Retevmo) with standard of care platinum-based chemotherapy and pembrolizumab (Keytruda). The primary end ..."

Published: Jul 30th, 2021 9:41 PM

Blueprint Medicines (BPMC) Misses on Q2 Earnings & Revenues

"In September 2020, the FDA approved Gavreto for the treatment of adults with metastatic RET fusion-positive non-small-cell lung cancer ("NSCLC")."

Published: Jul 30th, 2021 2:45 PM

What to know about thyroid cancer

"There are two types of medullary thyroid cancer: sporadic and familial. Most cases occur in younger people and are sporadic, where the cancer does not ..."

Published: Jul 29th, 2021 11:33 PM

Collaboration Plus Chemo, Surgery and CyberKnife Help Ag Teacher Beat Cancer

"... she was referred to hematologist-oncologist Michael Moffett at the Cancer Institute, who diagnosed her with metastatic medullary thyroid cancer and ..."

Published: Jul 29th, 2021 10:10 PM

Blueprint Medicines Q2 Revenues Increase More Than 200 Percent

"Blueprint's RET inhibitor pralsetinib (Gavreto), a drug for RET-altered, metastatic non-small cell lung and thyroid cancers, recorded $2.9 million in ..."

Published: Jul 28th, 2021 5:56 PM

Vandetanib and Cabozantinib Deemed Effective in Real-World Study of Medullary Thyroid Cancer

"Vandetanib and cabozantinib are "effective treatment options" in most patients with medullary thyroid cancer (MTC), according to researchers who ..."

Published: Jul 27th, 2021 9:41 PM

PNAS Papers on Rat Clues to Human Migration, Thyroid Cancer, PolyG-DS

"... two unrelated families affected by non-syndromic forms of familial, non-medullary thyroid cancer (FNMTC), identifying two loss-of-function mutations ..."

Published: Jul 27th, 2021 8:22 PM

Feasibility of lateral sentinel lymph node biopsy in medullary thyroid cancer: A surrogate tool for ...

"Feasibility of lateral sentinel lymph node biopsy in medullary thyroid cancer: A surrogate tool for determining prophylactic lateral neck dissection-A ..."

Published: Jul 25th, 2021 8:00 PM

Roundtable Discussion: Gadgeel Leads a Discussion on the Timing for RET-Targeted Therapy in ...

"RET mutations have also been observed [in NSCLC]. As we use what I call first-generation RET-specific drugs [pralsetinib (Gavreto) and selpercatinib ( ..."

Published: Jul 25th, 2021 5:11 PM

RET Mutations in Medullary Thyroid Are Cancer Viable for Multiple Targeted Agents

"... Oncology & Therapeutics Research at City of Hope, discussed the case of a 58-year-old man with RET-mutant medullary thyroid cancer (MTC)."

Published: Jul 24th, 2021 7:03 PM

Stephen Liu, MD, on Key Takeaways From the ARROW Trial of Pralsetinib for RET+ NSCLC

"... impact the treatment of patients with RET fusionpositive nonsmall cell lung cancer who are potential candidates for treatment with pralsetinib."

Published: Jul 21st, 2021 8:56 PM

Becoming Informed About Comprehensive Genomic Profiling

"There are ATA [American Thyroid Association] guidelines for medullary thyroid cancer that I've highlighted and read a million times, as Dr [Lori] Wirth ..."

Published: Jul 21st, 2021 4:26 AM

DC Circ. Won't Add To Novo Nordisk Whistleblower's Payout

"The drug has been linked to a rare cancer called medullary thyroid carcinoma, according to the federal government. Kennedy's suit asserted claims ..."

Published: Jul 18th, 2021 11:07 PM

Cabozantinib Appears to be a Promising New Treatment Option in Radioiodine-Refractory ...

"... COSMIC-311 trial indicated that cabozantinib elicited a promising survival benefit in patients with radioiodine-refractory differentiated thyroid cancer."

Published: Jul 17th, 2021 6:52 PM

Eric J. Sherman, MD, on Agents for Treating RET FusionPositive Thyroid Cancer

"Although only a subset of patients with papillary thyroid cancer have disease that is driven by RET fusions, over half of all patients with medullary ..."

Published: Jul 15th, 2021 12:07 PM

State institute cautions some patients against using Saxenda

"... patients with medullary thyroid cancer or a family history of such cancer, ... In addition, people with thyroid disease, mild or moderate hepatic ..."

Published: Jul 15th, 2021 6:18 AM

MedWatch Today: CyberKnife Stereotactic Radiosurgery Treats Rare Cancer

"Mindy was referred to hematologist-oncologist Michael Moffett at Community Cancer Institute,and diagnosed with metastatic medullary thyroid cancer."

Published: Jul 14th, 2021 7:03 PM

George Labonte: Concerns Upon a Diagnosis of Medullary Thyroid Cancer

"I went into the appointment expecting him to say that I have papillary thyroid cancer. He said there are four types of thyroid cancer, and I had medullary ..."

Published: Jul 14th, 2021 8:22 AM

Co-Occurrence of Familial Non-Medullary Thyroid Cancer (FNMTC) and Hereditary Non-Polyposis ...

"doi: 10.3389/fendo.2021.653401. eCollection 2021. ABSTRACT. Familial non-medullary thyroid cancer (FNMTC) is a form of endocrine malignancy ..."

Published: Jul 13th, 2021 7:37 PM

Rapid Readouts: Safety and Efficacy of Pralsetinib in Patients with Advanced RET Fusion-Positive ...

"Rapid Readouts: Safety and Efficacy of Pralsetinib in Patients with Advanced RET Fusion-Positive Non-Small Cell Lung Cancer: Update from the ..."

Published: Jul 12th, 2021 10:08 PM

Avanos Medical appoints general counsel

"Prior to Tmunity, James served as senior vice president and general counsel of Iroko Pharmaceuticals, and she began her life sciences legal career at ..."

Published: Jul 12th, 2021 8:56 PM

RET Fusion Inhibitor Proves Safe, Effective in NSCLC

"Consistent efficacy was seen with selpercatinib (Retevmo) in patients with RET fusion-positive non-small cell lung cancer (NSCLC), regardless of prior ..."

Published: Jul 10th, 2021 3:52 AM

EZH2i EPZ-6438 and HDACi vorinostat synergize with ONC201/TIC10 to activate integrated stress ...

"We hypothesized ONC201 sensitivity and tumor apoptosis may increase by reducing H3K27-methylation with EZH2i or HDACi as mimics of H3K27M- ..."

Published: Jul 7th, 2021 11:22 PM

Thyroid cancer: A worrying gastrointestinal symptom indicating your risk of the disease

"Severe diarrhoea is a very rare symptom sometimes found in people with advanced medullary thyroid cancer. The tumour produces high levels of ..."

Published: Jul 6th, 2021 8:00 PM

Roundtable Discussion: Brose Explores Selpercatinib and Pralsetinib in MTC

"Both selpercatinib (Retevmo) and pralsetinib (Gavreto) are FDA-approved therapies for RET-altered medullary thyroid cancer. The research ..."

Published: Jul 2nd, 2021 6:16 PM

Bauman Reviews Data for Patients With RET-Mutated NSCLC

"There is a label warning for tumor lysis syndrome with pralsetinib [in medullary thyroid cancer], which was not seen in the lung cancer cohort."

Published: Jul 1st, 2021 11:56 PM

Sherman Spotlights Advances With RET Inhibitors in Medullary Thyroid Cancer

"... the data supporting the regulatory approvals of selpercatinib (Retevmo) and pralsetinib (Gavreto), and future research directions with RET inhibitors ..."

Published: Jul 1st, 2021 5:22 AM

SGLT2 inhibitors and GLP-1 receptor agonists: established and emerging indications

"GLP-1 receptor agonists are contraindicated in those with a history of medullary thyroid cancer and used with caution in patients with a history of ..."

Published: Jun 30th, 2021 8:36 PM

Educating Patients on Germline and Somatic Testing

"Lori Wirth, MD: This question is really relevant for people with medullary thyroid cancer [MTC], where about 25% of medullary thyroid cancers occur in ..."

Published: Jun 28th, 2021 5:00 AM

CStone announces positive registrational study of GAVRETO (pralsetinib) in Chinese patients ...

"Key efficacy data for GAVRETO showed deep and durable anti-tumor activity in Chinese patients with advanced or metastatic RET-mutant medullary ..."

Published: Jun 27th, 2021 5:11 PM

New Recommendations Streamline Guidelines in Thyroid Cancer

"New Recommendations Streamline Guidelines in Thyroid Cancer ... Rarely, however, in patients with differentiated thyroid cancer (DTC) and ATC, ... thyroid and lung cancer, as well as for patients with RET-mutated medullary thyroid ..."

Published: Jun 25th, 2021 8:12 PM

In Brief This Week: Eli Lilly, Mirati Therapeutics, Legend Biotech, Personal Genome Diagnostics ...

"... metastatic or unresectable medullary thyroid cancer patients who are at least 12 years old; and for RET fusion-positive, metastatic thyroid cancer in ..."

Published: Jun 25th, 2021 5:11 PM

Overview and Diagnosis of Differentiated Thyroid Cancer

"All these subtypes are referred to as differentiated thyroid cancer to distinguish them from anaplastic thyroid cancer or medullary thyroid cancer."

Published: Jun 24th, 2021 8:09 PM

Multiple Agents Prove Useful in RET-Mutated Thyroid Cancer

"The preferred regimens are the multikinase inhibitors vandetanib [Caprelsa] and cabozantinib [Cabometyx]² and the [RET] inhibitors selpercatinib ..."

Published: Jun 24th, 2021 5:00 AM

CStone announces positive GAVRETO (pralsetinib) registrational study data for first-line ...

"GAVRETO is a potent and selective RET inhibitor discovered by CStone's partner Blueprint Medicines. "Platinum-based chemotherapy is recommended ..."

Published: Jun 22nd, 2021 5:00 PM

Stephen Liu, MD, on How Targeted Therapy Results in Significant Efficacy for RET-Altered Tumors

"... Stephen Liu, MD, discussed the important of findings from the ARROW trial of pralsetinib in patients with RET-altered nonsmall cell lung cancer."

Published: Jun 21st, 2021 5:16 PM

Notice of Compliance with Conditions granted for Retevmo (selpercatinib), the first therapy in ...

"Approved for metastatic RET fusion-positive non-small cell lung cancer, advanced or metastatic RET-mutant medullary thyroid cancer and advanced ..."

Published: Jun 21st, 2021 5:11 PM

Notice of Compliance with Conditions granted for Retevmo (selpercatinib), the first therapy in ...

"RET-mutant medullary thyroid cancer (MTC) in adult and pediatric patients 12 years of age and older with unresectable advanced or metastatic disease,."

Published: Jun 21st, 2021 5:00 PM

Notice of Compliance with Conditions granted for Retevmo (selpercatinib), the first therapy in ...

"Retevmo is indicated as monotherapy for the treatment of: metastatic RET fusion-positive non-small cell lung cancer (NSCLC) in adult patients,; RET- ..."

Published: Jun 21st, 2021 10:09 AM

CStone announces first prescriptions of precision therapy GAVRETO (pralsetinib) issued across ...

"With this milestone, GAVRETO, as the first approved selective RET inhibitor in China, can benefit Chinese patients. Currently, lung cancer is ranked the ..."

Published: Jun 19th, 2021 9:14 PM

Intracranial Efficacy of Selpercatinib in RET Fusion-Positive NonSmall Cell Lung Cancers on the ...

"Intracranial Efficacy of Selpercatinib in RET Fusion-Positive NonSmall Cell Lung Cancers on the LIBRETTO-001 Trial. Vivek Subbiah, Justin F."

Published: Jun 19th, 2021 9:14 PM

FDA Approval Summary: Pralsetinib for the Treatment of Lung and Thyroid Cancers With RET ...

"FDA Approval Summary: Pralsetinib for the Treatment of Lung and Thyroid Cancers With RET Gene Mutations or Fusions. Janice Kim, Diana Bradford, ..."

Published: Jun 19th, 2021 7:03 PM

For a bicyclist, a long overdue checkup uncovered the unexpected - The Washington Post

"MTC arises from the medulla inside the thyroid gland, which contains C ... making the malignancy difficult to detect - one reason medullary cancer ..."

Published: Jun 18th, 2021 8:56 AM

UPMC expert: Is cancer in your future?

"A rare cancer - such as male breast cancer, adrenal gland cancer, retinoblastoma, medullary thyroid cancer, or pheochromocytoma. A cancer that ..."

Published: Jun 17th, 2021 5:33 AM

Klotho Inhibits Proliferation in a RET Fusion Model of Papillary Thyroid Cancer by Regulating the ...

"... subtypes of thyroid cancer: papillary thyroid cancer (PTC) and follicular thyroid cancer (FTC) are the most common subtypes, and medullary thyroid ..."

Published: Jun 17th, 2021 1:48 AM

Start Thinking 'Cure'; One More Hug; Mortgages and Breast Cancer Survival

"Results of a phase I/II trial of the RET inhibitor pralsetinib (Gavreto) showed response rates of 60% to 90% in RET fusion-positive non-small cell lung ..."

Published: Jun 16th, 2021 5:22 PM

UPMC Expert: Is Your Future Cancer? | Life

"Rare cancers - male breast cancer, adrenal cancer, retinoblastoma, medullary thyroid cancer, pheochromocytoma, etc. Cancers that are likely to be ..."

Published: Jun 16th, 2021 2:26 AM

A study confirms the usefulness of a new drug for thyroid cancer

"Radiation therapy treatments to the head and neck increase the risk of thyroid gland cancer Certain inherited genetic syndromes. Familial medullary ..."

Published: Jun 12th, 2021 2:33 AM

Doctors Discuss the 'Game-Changing' Diet Drug Semaglutide

"Semaglutide carries a warning noting that it has been linked to medullary thyroid cancer, but this adverse effect has been reported only in studies on ..."

Published: Jun 11th, 2021 5:11 PM

LUNG CANCER

"In this multi-cohort, open-label, phase 1/2 study (ARROW), researchers tested pralsetinib (a highly potent, oral, selective RET inhibitor) for its safety, ..."

Published: Jun 10th, 2021 7:52 AM

Risk of Thyroid Cancer Associated with Use of Liraglutide and Other Antidiabetic Drugs in a US ...

"Thyroid cancer cases during follow-up were identified via a validated ... medullary thyroid carcinoma (MTC), the subtype that originates from C cells, ..."

Published: Jun 10th, 2021 6:27 AM

Targeted therapy pralsetinib safely effectively treats lung and thyroid cancers with RET alterations

"The ORR was 71% in patients with treatment-nave RET-mutant medullary thyroid cancer, 60% in patients previously treated with cabozantinib and/or ..."

Published: Jun 10th, 2021 4:16 AM

Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label ...

"Pralsetinib is a new, well-tolerated, promising, once-daily oral treatment option for patients with RET fusion-positive NSCLC. Funding. Blueprint ..."

Published: Jun 10th, 2021 3:30 AM

Targeted therapy pralsetinib safely effectively treats lung and thyroid cancers with RET alterations

"RET alterations are caused by a mutation in the DNA sequence and are oncogenic drivers in a variety of tumor types, most commonly in medullary ..."

Published: Jun 9th, 2021 7:37 PM

Comprehensive Genomic Profiling in Lung and Thyroid Cancer

"Another complicating layer consists of the germline mutations that are present in a subset of patients with medullary thyroid cancer vs the tumor ..."

Published: Jun 9th, 2021 6:29 PM

Thyroid cancer risk higher for menopausal women with longer reproductive years

"Of the cases, 90% were papillary thyroid cancer, 8% follicular and 2% medullary. Risk for thyroid cancer was more than double for women who had 41 ..."

Published: Jun 8th, 2021 8:00 PM

Novel Targeted Therapies Present Opportunities in Multiple Cancer Types

"Selpercatinib and pralsetinib are among the new options for RET fusion-positive non-small cell lung cancer (NSCLC), according to the presentation."

Published: Jun 8th, 2021 7:01 PM

Prior Therapy Does Not Influence Selpercatinib Efficacy in RET+ Medullary Thyroid Cancer

"Responses to selpercatinib in patients with pretreated medullary thyroid cancer were noted irrespective of therapy regimens received in prior lines, ..."

Published: Jun 8th, 2021 6:52 PM

Prior Therapy Does Not Influence Selpercatinib Efficacy in RET+ Medullary Thyroid Cancer

"Responses to selpercatinib in patients with pretreated medullary thyroid cancer were noted irrespective of therapy regimens received in prior lines, ..."

Published: Jun 7th, 2021 7:03 PM

Pediatric Patients With RET-Altered Tumors Experience Tumor Responses With Selpercatinib

"... Oncology (ASCO) Annual Meeting demonstrated antitumor activity of selpercatinib (Retevmo) in pediatric patients with RET-altered solid tumors.¹."

Published: Jun 7th, 2021 2:56 AM

Selpercatinib Improves Responses Regardless of Prior Treatment in RET-Mutant Medullary ...

"Selpercatinib (Retevmo) improved overall response rates (ORRs) in most patients with RET-mutatedmedullary thyroid cancer (MTC) irrespective of ..."

Published: Jun 7th, 2021 12:07 AM

Retevmo Shows Improvement for Previously Treated Patients With Non-Small Cell Lung Cancer

"The objective response rate with Retevmo was 57% which was "markedly higher," the researchers wrote, than responses for prior treatment at 16%. A ..."

Published: Jun 7th, 2021 12:00 AM

Retevmo Shows Improvement for Previously Treated Patients With Non-Small Cell Lung Cancer

"Retevmo (selpercatinib) demonstrated response improvements in previously treated patients with RET fusion-positive non-small cell lung cancer ..."

Published: Jun 6th, 2021 11:44 PM

Selpercatinib Improves Responses Regardless of Immediate Prior Treatment in RET-Mutant ...

"Selpercatinib improved overall response rates in most patients with RET-mutated medullary thyroid cancer irrespective of prior systemic therapy. figure ..."

Published: Jun 6th, 2021 6:30 PM

Better Responses Observed With Selpercatinib Versus Prior Systemic Therapies for RET+ NSCLC

"Compared with immediate prior therapy, selpercatinib resulted in a greater proportion of objective responses in patients with nonsmall cell lung ..."

Published: Jun 6th, 2021 5:11 PM

Pralsetinib Shows Durable Anti-Tumor Activity in Study Update for RET+ Solid Tumors

"... medullary thyroid cancer or RET fusionpositive thyroid cancer.² This trial is still enrolling patients with other RET fusionpositive solid tumors.¹."

Published: Jun 5th, 2021 11:33 PM

Selpercatinib May be an Effective NSCLC Treatment

"Consistent efficacy was seen with selpercatinib in patients with RET fusion-positive non-small cell lung cancer, regardless of prior treatments. Consistent ..."

Published: Jun 5th, 2021 11:22 PM

Selpercatinib Effective in Treating NSCLC

"Treatment with selpercatinib (Retevmo) demonstrated consistent efficacy in patients with RET fusion-positive non-small cell lung cancer (NSCLC), ..."

Published: Jun 5th, 2021 11:02 PM

Gavreto 'Very Well Tolerated' in RET Fusion-Positive Non-Small Cell Lung Cancer

"Currently, Gavreto is approved in the U.S. for treatment of RET fusion-positive NSCLC and advanced or metastatic RET- altered thyroid cancers. The ..."

Published: Jun 5th, 2021 10:15 PM

ARROW Update Shows Pralsetinib Has Durable Anti-Tumor Activity in RET+ Solid Tumors

"... or more, with advanced or metastatic RET-mutant medullary thyroid cancer or RET fusionpositive thyroid cancer.² This trial is still enrolling patients ..."

Published: Jun 5th, 2021 10:06 PM

Pralsetinib Elicits Durable Anti-Tumor Effects in RET Fusion+ Solid Tumors

"Pralsetinib (Gavreto) demonstrated robust and durable anti-tumor activity, as well as a tolerable safety profile, in heavily pretreated patients with ..."

Published: Jun 5th, 2021 7:24 PM

US FDA approves obesity drug Wegovy which helped people cut weight by 15%. All you need to ...

"FDA has warned against its use in patients with a personal or family history of medullary thyroid carcinoma or in patients with a rare condition called ..."

Published: Jun 5th, 2021 9:22 AM

Cancer symptoms: Expert uncovers five key signs of a growing thyroid tumour

""Patients with thyroid cancer usually have normal thyroid function blood tests," cautioned Dr Jeannon. Thus, people need to be aware of the physical ..."

Published: Jun 5th, 2021 8:00 AM

Cancer symptoms: Expert uncovers five key signs of a growing thyroid tumour

""Patients with thyroid cancer usually have normal thyroid function blood tests," cautioned Dr Jeannon. Thus ... Medullary Thyroid Cancer (MTC)."

Published: Jun 4th, 2021 10:37 PM

ARROW Trial Update Continues to Support Pralsetinib Use, Biomarker Testing in RET Fusion+ ...

"Durable responses coupled with a tolerable safety profile of pralsetinib (Gavreto) in patients with RET fusionpositive nonsmall cell lung cancer ..."

Published: Jun 4th, 2021 9:52 PM

Pralsetinib Tolerable, Durable in RET Fusion-Positive Non-Small Cell Lung Cancer

"Pralsetinib (Gavreto) was well-tolerated and showed durable responses in patients with RET fusion-positive non-small cell lung cancer (NSCLC), ..."

Published: Jun 4th, 2021 5:00 PM

Stephen V. Liu, MD, Discussed the Importance of Testing for Oncogenic Drivers in Frontline NSCLC

"CancerNetwork sat down with Stephen V. Liu, MD, at the 2021 American Society of Clinical Oncology Annual Meeting to talk about pralsetinib for ..."

Published: Jun 4th, 2021 3:41 AM

CAR T-Cell Therapy Trial in Solid Tumors Halted Following 2 Patient Deaths

"Tmunity Therapeutics, a clinical-stage biotherapeutics company, has halted the development of its lead CAR T-cell product following the deaths of 2 ..."

Published: Jun 3rd, 2021 5:45 PM

Tmunity stops solid tumor CAR-T trial after 2 patients die

"Tmunity Therapeutics has stopped development of its lead CAR-T therapy after two patients died of a form of neurotoxicity. The news, details of which ..."

Published: Jun 2nd, 2021 10:37 PM

Dr. Carl June's drugmaker scraps lead CAR-T program after 2 trial participants die

"Tmunity was founded in 2015 by Oz Azam, MD, and Carl June, MD, the famed immunologist who pioneered T-cell therapies for cancer. Both physicians ..."

Published: Jun 2nd, 2021 8:00 PM

Exclusive: Carl June's Tmunity encounters a lethal roadblock as 2 patient deaths derail lead trial ...

"In exclusive interviews, Tmunity founders Carl June and Oz Azam tell me that they have had to scrap their lead program for prostate cancer following ..."

Published: Jun 2nd, 2021 1:22 PM

Thyroid Cancer Therapeutics Market Strategies and Insight Driven Transformation 2021-2028

"Market Segmentation: By Type (Papillary Thyroid Cancer, Follicular Thyroid Cancer, Medullary Thyroid Cancer (MTC), Anaplastic Thyroid Cancer, ..."

Published: May 26th, 2021 9:30 PM

Dr. Owonikoko on the Efficacy of Selpercatinib in Pre-Treated and Untreated RET+ Thyroid Cancer

"... discusses the efficacy of selpercatinib (Retevmo) in pre-treated and treatment-naive patients with RET fusionpositive medullary thyroid cancer."

Published: May 26th, 2021 1:16 PM

All You Need to Know About Thyroid Cancer

"Nearly 20% of the medullary thyroid cancer cases are due to the patient's inheritance of an abnormal gene from his/her parents. 2] Deficiency of Iodine ..."

Published: May 25th, 2021 11:22 PM

Platelet-Derived Growth Factor Receptor-alpha Subunit Targeting Suppresses Metastasis in ...

"Thyroid cancer is the most common endocrine malignancy. ... However, poorly differentiated thyroid cancers, such as medullary, squamous and ..."

Published: May 25th, 2021 11:55 AM

Demi Jones' heartbreak as she reveals 'nasty' trolls claimed she LIED about her thyroid cancer ...

"Demi said she is speaking out about her thyroid cancer battle to help others push ... The cells within the thyroid grow too quickly and create a lump. ... types which include: papillary carcinoma, follicular carcinoma, medullary thyroid ..."

Published: May 24th, 2021 8:45 PM

Even as many stocks tumble, Exelixis Inc. (EXEL) seems promising

"The FDA extended the indications for Cabometyx (previously only available for treating medullary thyroid cancer) at the end of January this year."

Published: May 24th, 2021 6:53 PM

Love Island's Demi Jones puts on a brave face for a night out three days after revealing she's got ...

"Thyroid cancer develops in your thyroid gland, which is located in your neck, and is ... The cells within the thyroid grow too quickly and create a lump. ... types which include: papillary carcinoma, follicular carcinoma, medullary thyroid ..."

Published: May 22nd, 2021 2:22 AM

RET Fusion Inhibitor Active Beyond Lung, Thyroid Cancers

"The RET inhibitor selpercatinib (Retevmo) exhibited clinical activity in almost half of patients with non-lung/non-thyroid cancers associated with RET ..."

Published: May 20th, 2021 11:33 PM

Blueprint Medicines, Genentech to Discuss With Regulators Gavreto's Activity in RET-Altered Tumors

"The accelerated approval of pralsetinib in RET fusion-positive, metastatic NSCLC was based on an overall response rate of 70 percent in treatment- ..."

Published: May 20th, 2021 7:40 PM

Love Island's Demi Jones devastated as doctors tell her she's got thyroid cancer after operation to ...

"The cells within the thyroid grow too quickly and create a lump. There are four types which include: papillary carcinoma, follicular carcinoma, medullary ..."

Published: May 20th, 2021 2:29 AM

Dr. Niu on Selecting Between Selpercatinib and Pralsetinib in RET Fusion+ NSCLC

"Regarding safety, selpercatinib can cause QT prolongation, which needs to be managed, says Niu. Other agents commonly utilized in lung cancer, such ..."

Published: May 20th, 2021 2:08 AM

Chimerix Announces Upcoming Presentations at the American Society of Clinical Oncology 2021 ...

"ONC201 is currently in a registrational clinical program for recurrent H3 K27M-mutant glioma and a blinded independent central review is expected ..."

Published: May 18th, 2021 6:07 PM

Mutational Risk Not Associated With Distant Metastasis in Medullary Thyroid Cancer

"The risk of distant metastasis is rare when thyroidectomy is performed before lymph node involvement occurs in patients with medullary thyroid cancer ..."

Published: May 17th, 2021 11:11 PM

Persistence of Elevated Procalcitonin in a Patient with Covid-19 Uncovering a Diagnosis of ...

"... during recovery prompted the diagnosis of medullary thyroid cancer (MTC). ... calcifications and a non-homogeneous thyroid with multiple nodules."

Published: May 17th, 2021 6:12 PM

Turning Point Therapeutics Names Kumar Srinivasan as Executive Vice President, Chief Business ...

"... being studied in a Phase 1 trial of patients with advanced or metastatic solid tumors harboring genetic alterations in MET; TPX-0046, targeting RET, ..."

Published: May 14th, 2021 4:45 PM

Kept an ocean away from its scientific advisors, Shanghai's Elpiscience keeps up the clinical ...

"Exclusive: Carl June's Tmunity encounters a lethal roadblock as 2 patient deaths derail lead trial, raise red flag forcing a rethink of CAR-T for solid tumors ..."

Published: May 13th, 2021 4:26 PM

Tetanus Toxoid Vaccine Market | Analysis of Market by Product Type, Top Manufacturers, Key ...

"Market Segmentation: By Component: By Type (Papillary Thyroid Cancer, Follicular Thyroid Cancer, Medullary Thyroid Cancer (MTC), Anaplastic ..."

Published: May 8th, 2021 2:45 AM

Patient With RET-Mutated Lung Cancer Is Eligible for Therapy With Selpercatinib or Pralsetinib

"... [selective RET inhibitor] agents [selpercatinib (Retevmo) and pralsetinib (Gavreto)] that are approved now as a frontline therapy,1 and so that's why, ..."

Published: May 7th, 2021 11:11 PM

Exelixis (EXEL) Q1 Earnings Miss Estimates, Revenues Beat

"... of medullary thyroid cancer generated $3.6 million in net product revenues. ... antitumor activity of XB002 in patients with advanced solid tumors."

Published: May 7th, 2021 8:07 PM

Efficacy of Selpercatinib in RET Fusion-Positive Thyroid Cancers

"Vivek Subbiah, MD, discusses the updated results of the LIBRETTO-001 trial, specifically the effect of selpercatinib on RET fusion-positive thyroid tumors ..."

Published: May 7th, 2021 4:37 PM

Glioblastoma Pipeline Analysis: 60+ Key Pipeline Therapies and 60+ Key Pharma Players are ...

"Similarly, ONC201 and CAN008 are undergoing Phase II development phase for Glioblastoma. Glioblastoma pipeline therapies in the early stage of ..."

Published: May 7th, 2021 3:07 PM

The Smartest Stocks to Buy With $50 Right Now

"For context, the Cabometyx franchise, which includes sales of medullary thyroid cancer drug Cometriq, totaled almost $742 million in 2020."

Published: May 6th, 2021 9:07 PM

Method for Targeting RET in Thyroid Cancers and Other RET+ Advanced Cancers

"... medullary thyroid cancer (MTC) who require systemic therapy, and those with advanced or metastatic RET fusion-positive thyroid cancer who ..."

Published: May 6th, 2021 3:41 AM

Tumor Agnostic RET Inhibition: The ARROW Trial

"Jyoti Patel, MD, FASCO: Thank you for that. The ARROW trial was a registrational phase 1/2 study design in which MTC [medullary thyroid cancer] and ..."

Published: May 6th, 2021 3:28 AM

Tumor Agnostic RET Inhibition: The LIBRETTO-001 Trial

"Lori Wirth, MD: One thing I want to comment on is that, interestingly, the dirty kinases like vandetanib used in MTC [medullary thyroid cancer] have ..."

Published: May 5th, 2021 3:07 PM

Tag: United States Medullary Thyroid Cancer Market

"Medullary Thyroid Cancer Market Size 2021 Industry Share, Strategies, Growth Analysis, Regional Demand, Revenue, Key Players and 2027 ..."

Published: May 5th, 2021 2:21 AM

Dr. Shafique on Selecting Between Selpercatinib and Pralsetinib in RET+ NSCLC

"... considerations for selecting between selpercatinib (Retevmo) and pralsetinib (Gavreto) in RET fusionpositive nonsmall cell lung cancer (NSCLC)."

Published: May 4th, 2021 4:21 PM

UPDATED: Pfizer hits the brakes on their pivotal trial for a BCMA/CD3 bispecific on safety concerns ...

"What started as a voluntary halt by Tmunity in the face of these deaths flipped to an FDA-enforced red light for the clinical trial, while the biotech ..."

Published: May 4th, 2021 2:22 AM

Week In Review: CANbridge Licenses LogicBio's Adeno-Associated Virus For Gene Therapies In ...

"Discovered by CStone's partner Blueprint Medicines, Gavreto is approved in the US and is the first approved selective RET inhibitor in China."

Published: May 2nd, 2021 5:56 PM

Brose Explores Treatments for a Patient With RET-Mutated Thyroid Cancer

"Targeted Oncology^TM: For a patient with medullary thyroid cancer (MTC), is there a situation where you would consider watching and waiting instead of ..."

Published: Apr 30th, 2021 7:03 PM

Blueprint Medicines (BPMC) Q1 Earnings Beat, Revenues Lag

"In September 2020, the FDA approved Gavreto for the treatment of adults with metastatic RET fusion-positive non-small-cell lung cancer ("NSCLC")."

Published: Apr 29th, 2021 11:00 PM

Researchers Weigh Benefits, Costs of Screening Newborns for Cancer Risk Mutations

"... APC, ALK, and PHOX2B, which are associated with increased risk of childhood medullary thyroid cancer, retinoblastoma, adrenocortical carcinoma, ..."

Published: Apr 29th, 2021 4:34 AM

For ASU film grad, laughter really is the best medicine

"Since 2014, Lew has been battling stage 4 medullary thyroid cancer and undergoing chemotherapy treatments. A working comedian, Lew's motto is "If ..."

Published: Apr 29th, 2021 2:31 AM

LIBRETTO-001 and ARROW Trials Show Positive Data in RET FusionPositive Lung Cancer

"... multiple different malignances, the most common being papillary thyroid cancer, medullary thyroid cancer, and nonsmall cell lung cancer [NSCLC], ..."

Published: Apr 28th, 2021 1:54 AM

Metastatic leiomyosarcoma of the thyroid: A rare entity

"Cancer metastasis to the thyroid gland from non-thyroid sites is a rare ... carcinoma (UTC) with a sarcomatoid pattern, medullary thyroid carcinoma ..."

Published: Apr 27th, 2021 9:02 PM

Post-Hoc Analysis of Pivotal Trial Demonstrates Safety of Selpercatinib in RET-Altered Advanced ...

"Low-grade, manageable treatment-emergent adverse effects and low rates of discontinuation were associated with the RET inhibitor selpercatinib as ..."

Published: Apr 27th, 2021 12:07 AM

RET Inhibition Holds Tumor-Agnostic Potential

"... for patients with NSCLC and radioactive iodinerefractory thyroid cancer harboring RET fusions and for RET-mutant medullary thyroid cancer (MTC)."

Published: Apr 26th, 2021 6:52 PM

Roundtable Discussion: Treating Radioiodine-Refractory Differentiated Thyroid Cancer

"... cancer-whether it's DTC, anaplastic thyroid cancer, or even medullary thyroid cancer-thyroid cancers harbor a high rate of actionable alterations."

Published: Apr 26th, 2021 6:29 PM

CStone Announces NMPA Acceptance of New Drug Application of Selective Inhibitor GAVRETO(R ...

"In March 2021, the NMPA granted approval of pralsetinib under the brand name GAVRETO for the treatment of adult patients with locally advanced ..."

Published: Apr 26th, 2021 6:18 PM

CStone Announces NMPA Acceptance of New Drug Application of Selective Inhibitor GAVRETO(R ...

"This may expand the labeled indications for GAVRETO in China to include advanced or metastatic RET-mutant medullary thyroid cancer (MTC) who ..."

Published: Apr 23rd, 2021 5:34 PM

Clinical context crucial when treating thyroid cancer in older adults

"For those with medullary thyroid cancer, a higher proportion died of thyroid cancer initially, but the proportion of those dying of other causes was ..."

Published: Apr 22nd, 2021 7:26 PM

'Desperate appeal' for 32-year-old fighting aggressive cancer who needs 10000 a month for ...

"Tayo Bolakale Salau has been fighting medullary thyroid carcinoma, an extremely rare and aggressive form of cancer since 2015. Since his diagnosis ..."

Published: Apr 22nd, 2021 3:52 PM

Julie Rose, of Bridgwater, told rare cancer has spread

""It was explained I had a rare type of thyroid cancer called Medullary thyroid cancer. "I broke down at the shock of the news and fired a million questions ..."

Published: Apr 21st, 2021 3:42 AM

Lilly Presents New Data on selpercatinib in Advanced RET Fusion-Positive Gastrointestinal and ...

"... trial showing treatment with selpercatinib demonstrated encouraging antitumor activity and safety across RET fusion-positive advanced solid tumors ..."

Published: Apr 21st, 2021 3:41 AM

Lilly Presents New Data on selpercatinib in Advanced RET Fusion-Positive Gastrointestinal and ...

"i RETEVMO [package insert]. Indianapolis, IN: Eli Lilly and Company; 2021. SOURCE Eli Lilly Canada Inc. For further information: Media Contact: ..."

Published: Apr 20th, 2021 1:48 AM

A Remarkable and Durable Response to Sintilimab and Anlotinib in the First-Line Treatment of an ...

"Abstract: Anaplastic thyroid carcinoma (ATC) is a rare and highly ... For 58 patients with locally advanced or metastatic medullary thyroid cancer who ..."

Published: Apr 20th, 2021 12:07 AM

McIver Explores Treatment of a Patient With RET-Mutated Medullary Thyroid Cancer

"... and deputy physician-in-chief at Moffitt Cancer Center, discussed the case of a 58-year-old patient with RET-mutant medullary thyroid cancer (MTC)."

Published: Apr 19th, 2021 10:37 AM

Global Cabozantinib Market 2021 Top Industry Trend and Segments Analysis upto 2026

"Medullary Thyroid Cancer Treatment; Second Line Treatment for Renal Cell Carcinoma. On the basis of geographical boundaries, the market is ..."

Published: Apr 17th, 2021 6:47 AM

Vivek Subbiah on RET FusionPositive Cancers Efficacy of Selpercatinib - The ASCO Post

"Vivek Subbiah, MD, of The University of Texas MD Anderson Cancer Center, discusses data on selpercatinib that showed promising activity across a ..."

Published: Apr 15th, 2021 5:00 PM

Retevmo Is Active Against Multiple Types of Advanced Cancer

"The overall response rate was 69% for previously treated and 73% for treatment-naive people with medullary thyroid cancer with RET mutations, and ..."

Published: Apr 13th, 2021 8:42 PM

AACR Study of Eli Lilly's Retevmo Shows Anti-Tumor Activity Across Cancers

"NEW YORK Eli Lilly's selpercatinib (Retevmo) demonstrated anti-tumor activity in a range of RET fusion-positive tumors, according to data ..."

Published: Apr 13th, 2021 4:15 PM

Lilly's RET inhibitor Retevmo shows early promise in new cancer types

""We are excited to broaden the body of evidence for Retevmo in RET fusion-positive cancers beyond lung and thyroid tumours," said David Hyman, chief ..."

Published: Apr 13th, 2021 4:37 AM

Retevmo (selpercatinib) Demonstrates Activity Against Advanced RET Fusion Positive Advanced ...

"12 Apr Retevmo (selpercatinib) Demonstrates Activity Against Advanced RET Fusion Positive Advanced Solid Tumors. Posted at 23:39h in AACR, ..."

Published: Apr 13th, 2021 2:22 AM

Selpercatinib plus Crizotinib May Help Target MET-Dependent Resistance in RET+ NSCLC

""Selpercatinib is a highly selective RET kinase inhibitor that has recently been approved by the FDA in lung and thyroid cancers with activating RET ..."

Published: Apr 12th, 2021 9:30 PM

Lilly's Retevmo shows encouraging antitumour activity in cancer trial

"Eli Lilly and Company has reported that first-time data from the Phase I/II LIBRETTO-001 trial of Retevmo (selpercatinib) treatment showed promising ..."

Published: Apr 12th, 2021 9:07 PM

MD Anderson researchers highlight advances in clinical studies at the AACR Annual Meeting 2021

"Selpercatinib became the first treatment approved by the Food and Drug Administration (FDA) to treat RET fusion-positive lung and thyroid cancers, as ..."

Published: Apr 12th, 2021 7:55 PM

New Data on Selpercatinib Shows Promise for Certain Gastrointestinal Malignancies and Other ...

"Selpercatinib (Retevmo; Eli Lilly and Company) demonstrated encouraging antitumor activity and safety across RET fusion-positive advanced solid ..."

Published: Apr 12th, 2021 7:48 PM

New Data on Selpercatinib Shows Promise for Certain Gastrointestinal Malignancies and Other ...

"... lung cancer, in adult and pediatric patients ages 12 years and older with advanced or metastatic RET-mutant medullary thyroid cancer who require ..."

Published: Apr 12th, 2021 5:33 PM

Progress In Treating Hodgkin Lymphoma

"Separately, retevmo, a drug from Eli Lilly already approved for lung and thyroid cancer treatments, has shown promise in beating rare tumors found ..."

Published: Apr 11th, 2021 11:41 PM

AACR: A 'tissue agnostic' indication for Retevmo? Lilly says it's possible with RET cancer win

"Eli Lilly's Retevmo is already approved to treat lung and thyroid cancers driven by alterations in the RET gene. Now, the Indianapolis pharma believes it ..."

Published: Apr 11th, 2021 11:22 PM

MD Anderson researchers highlight advances in clinical studies at the AACR Annual Meeting 2021

"... Administration (FDA) to treat RET fusion-positive lung and thyroid cancers, as well as RET-mutant medullary thyroid cancer (MTC), in May 2020."

Published: Apr 11th, 2021 11:00 PM

Lilly's Retevmo shows success in rare tumors. But can doctors identify the patients who would be ...

"Retevmo, a drug developed by Eli Lilly's Loxo Oncology unit, shows efficacy in tumors beyond the lung and thyroid cancers where it is approved so ..."

Published: Apr 11th, 2021 8:33 PM

Selpercatinib Demonstrates Favorable Safety Profile in RET-Altered Advanced Solid Tumors

"Selpercatinib (Retevmo) demonstrated a favorable safety profile, characterized by low-grade treatment-emergent adverse effects (TEAEs), ..."

Published: Apr 10th, 2021 7:20 PM

Dr. Besse on the Safety of Selpercatinib in Advanced RET+ Thyroid Cancer, NSCLC

"... the use of selpercatinib (Retevmo) in patients with RET-altered advanced medullary thyroid cancer and nonsmall cell lung cancer (NSCLC)."

Published: Apr 10th, 2021 7:15 PM

Dr. Besse on the Safety of Selpercatinib in Advanced RET+ Thyroid Cancer, NSCLC

"In total, 702 patients were enrolled to the trial, a majority of whom had NSCLC or medullary thyroid cancer. AEs were found to be dose dependent, with ..."

Published: Apr 10th, 2021 12:52 AM

Subbiah Explores Treatment of NonSmall Cell Lung Cancer With a KIF5B-RET Fusion

"It's seen in 10% to 20% of papillary thyroid cancers. In medullary thyroid cancer [MTC], almost 100% of the patients with a hereditary form of thyroid ..."

Published: Apr 9th, 2021 8:56 PM

Gavreto From Blueprint Medicines Corporation

"... metastatic RET-mutant medullary thyroid cancer (MTC) requiring systemic therapy, and advanced or metastatic RET fusionpositive thyroid cancer ..."

Published: Apr 9th, 2021 8:15 AM

Correlation between preoperative ultrasonic features of medullary thyroid carcinoma and ...

"This retrospective study was conducted to determine factors impacting postoperative recurrence in patients suffering from medullary thyroid carcinoma ..."

Published: Apr 9th, 2021 1:08 AM

Chimerix Announces Upcoming Presentations at the American Association for Cancer Research ...

"ONC201: Characterization and combinatorial efficacy in brain tumors ... Title: ONC201 as a novel anti-cancer therapeutic via modulation of inhibitors ..."

Published: Apr 8th, 2021 5:26 PM

Global Cabozantinib Market 2020-2025 Business Insights and Sustainable Growth in Respective ...

"On the basis of application, the market is segmented into: Medullary Thyroid Cancer Treatment, Second Line Treatment for Renal Cell Carcinoma,."

Published: Apr 8th, 2021 4:13 PM

The Four Stages of a Global Pandemic Global neuroendocrine tumors market In-Depth Analysis ...

"Global neuroendocrine tumors market research report is sure to help ... tumors in the lungs; Pancreatic neuroendocrine tumors; Medullary thyroid ..."

Published: Apr 7th, 2021 10:37 PM

Global Glioblastoma Pipeline Insight 2021: Comprehensive Insights About 150+ Companies and ...

"The drug is being studied in phase II/III for the treatment of Glioblastoma. ONC-201: Oncotherapeutics. ONC201 is a highly selective antagonist of ..."

Published: Apr 7th, 2021 5:22 PM

TPTX Stock Prices Decreased by -8.44%: Here's Why It Happened

"... study including 10 with non-small cell lung cancer (NSCLC) and 11 with medullary thyroid carcinoma (MTC) who were treated from December 2019 ..."

Published: Apr 7th, 2021 12:07 PM

How it works: Combination therapy for type 2 diabetes

"For example, people with medullary thyroid cancer should not take GLP-1 RAs or DPP-4 inhibitors. Moreover, people with heart failure or liver disease ..."

Published: Apr 7th, 2021 1:03 AM

Health Care Sector Update for 04/06/2021: TPTX,CARA,ILMN,MITO,ALXN

"... preliminary clinical activity with tumor regression during phase I/II testing in patients with non-small cell lung cancer or medullary thyroid carcinoma."

Published: Apr 6th, 2021 10:03 PM

Turning Point Therapeutics Shares Initial Data on RET Inhibitor, Anticipates FDA Meeting

"... presented preliminary data from the Phase I/II trial involving 21 patients, 10 with non-small cell lung cancer and 11 with medullary thyroid carcinoma."

Published: Apr 6th, 2021 8:56 PM

Investigational RET Inhibitor TPX-0046 Show Preliminary Clinical Activity in NSCLC, MTC

"In a dose-finding trial, TPX-0046 elicited responses in patients with nonsmall cell lung cancer and medullary thyroid cancer who were nave to prior ..."

Published: Apr 6th, 2021 12:52 AM

Turning Point Therapeutics Announces Initial Clinical Data From Phase 1/2 SWORD-1 Study of ...

""While we continue to evaluate TPX-0046, the initial preliminary data are encouraging, with a generally tolerable safety profile and early signals of ..."

Published: Apr 5th, 2021 7:54 PM

2400 people remain without rare disease drug as Takeda manufacturing woes continue

"Since the Natpara recall in September 2019, no US revenue has been recorded and the concerns are growing. "We've been told that they plan to keep ..."

Published: Apr 5th, 2021 9:18 AM

'Panicked' Wilton family takes son with cancer to Vermont for COVID vaccine

"According to the American Thyroid Association, Medullary thyroid cancer accounts for 1 to 2 percent of thyroid cancers in the United States. Receiving ..."

Published: Apr 2nd, 2021 3:30 PM

GSK sells royalty rights on cancer drugs for nearly $400 million

"Cometriq is approved for progressive, metastatic medullary thyroid cancer. Cabometyx and Cometriq are marketed by Exelixis (Nasdaq: EXEL) in the ..."

Published: Apr 1st, 2021 11:56 PM

How is thyroid cancer treated?

"Medullary thyroid cancer, a type of neuroendocrine cancer that begins in the T cells of the thyroid. These are the cells that help maintain a healthy ..."

Published: Apr 1st, 2021 2:22 AM

Turning Point Therapeutics Announces Board Changes Nasdaq:TPTX

"... being studied in a Phase 1 trial of patients with advanced or metastatic solid tumors harboring genetic alterations in MET; TPX-0046, targeting RET, ..."

Published: Mar 31st, 2021 11:22 PM

Multiple Trial Regimens Demonstrate Efficacy for RET-Mutated Medullary Thyroid Cancer

"When MTCs [medullary thyroid cancers] are not highly FDG [fluorodeoxyglucose] avid, and because they are neuroendocrine tumors with somatostatin ..."

Published: Mar 31st, 2021 9:30 PM

Kazim Bayus

"In March 2019, Kazim was diagnosed with medullary thyroid cancer at Yale New Haven Hospital. Soon after moving to Massachusetts, Kazim ..."

Published: Mar 30th, 2021 4:48 PM

Exelixis: A Look At Its Potential

"COMETRIQ is used to treat people with medullary thyroid cancer (MTC) that has spread to other parts of the body (called metastatic MTC). COTELLIC ..."

Published: Mar 29th, 2021 11:22 PM

The Impact of Somatic and Germline RET Mutations in Medullary Thyroid Cancer

"... at the University of Texas MD Anderson Cancer Center, explains what sets medullary thyroid cancer apart from other thyroid cancer histologies."

Published: Mar 27th, 2021 2:22 AM

Cstone scores approval for Blueprint Medicines' Gavreto in China

"... RET-mutant medullary thyroid cancer and other advanced solid tumors with RET ... including first-line NSCLC, thyroid cancer and other solid tumors."

Published: Mar 26th, 2021 4:37 AM

Thyroid and COVID-19: a review on pathophysiological, clinical and organizational aspects

"... and reorganization of healthcare services may affect thyroid disease ... "thyroid nodule", "differentiated thyroid cancer", "medullary thyroid cancer", ..."

Published: Mar 25th, 2021 11:11 PM

RET inhibitors for lung cancer: What to know

"RET inhibitors target cancers that have RET gene mutations. These include non-small cell lung cancer (NSCLC), medullary thyroid cancer, and ..."

Published: Mar 24th, 2021 8:00 PM

Blueprint Medicines partner CStone wins Chinese approval for lung cancer therapy

"... CStone for the development and commercialization of pralsetinib and certain other candidates in Mainland China, Hong Kong, Macau, and Taiwan."

Published: Mar 24th, 2021 3:18 PM

RET Inhibitors Drug Retevmo Gavreto Market Size Clinical Trials Insight 2026

"RET Inhibitors Drug Retevmo Gavreto Market Size Clinical Trials Insight 2026 · Global RET Inhibitors Market Opportunity: > USD 1.5 Billion · Global RET ..."

Published: Mar 24th, 2021 7:54 AM

CStone Announces New Drug Approval of GAVRETO(R) (pralsetinib) as First Selective RET ...

"... RET-mutant medullary thyroid cancer, and other advanced solid tumors ... Among all Chinese cancer patients, lung cancer is the leading cause of ..."

Published: Mar 24th, 2021 7:26 AM

Teen cancer patient joins list of CT residents who've turned to other states for COVID-19 vaccine

"Schwartz was diagnosed with medullary thyroid cancer amid the pandemic and is at an all-time high for severe complications with COVID-19 - and it's ..."

Published: Mar 23rd, 2021 8:20 PM

La medicina de precisin llega al cncer de tiroides con fusin del gen RET positiva

"Selpercatinib est indicado para pacientes con tumores de tiroides, bien con mutacin o fusin del gen RET, en los cuales ya hay metstasis a partir de ..."

Published: Mar 22nd, 2021 4:37 PM

With early phase 2 data, BridgeBio plots next steps for hypoparathyroidism drug

"The FDA approved NPS Pharma's hormonal injection, Natpara, in 2015, after granting it orphan designation. But the medicine's new owner Takeda ..."

Published: Mar 19th, 2021 7:48 PM

Blueprint Medicines (BPMC) Up 2.1% Since Last Earnings Report: Can It Continue?

"Revenues include $6 million of net product revenues from the sales of Ayvakit and $0.7 million from Gavreto. Collaboration revenues were $27.4 ..."

Published: Mar 17th, 2021 8:40 PM

Real-World Study Shows Vandetanib and Cabozantinib Effective for Advanced MTC

""Management of patients with advanced medullary thyroid cancer remains a therapeutic challenge. The multi-tyrosine kinase inhibitors (TKIs) ..."

Published: Mar 16th, 2021 1:42 AM

Ca19.9 Positivity Indicative of Mortality from Medullary Thyroid Cancer

"In advanced medullary thyroid cancer (MTC), mortality may be predicted by serum carbohydrate antigen 19.9 (Ca19.9) positivity in patients as well as ..."

Published: Mar 15th, 2021 6:18 PM

Selpercatinib and Pralsetinib Generate Enthusiasm in RET Fusion+ NSCLC

"The RET inhibitors selpercatinib (Retevmo) and pralsetinib (Gavreto) demonstrated high response rates in both treatment-nave and pretreated ..."

Published: Mar 15th, 2021 5:11 PM

Increase in Thyroid Cancer Rates Points to Overscreening

"Rates for medullary thyroid cancer were less than one per 100,000 person-years among men and women. For the anaplastic subtype, rates were less ..."

Published: Mar 12th, 2021 10:15 PM

Why Is Exelixis (EXEL) Up 3.4% Since Last Earnings Report?

"Cometriq (cabozantinib capsules) for the treatment of medullary thyroid cancer generated $4 million in net product revenues. Exelixis earned $23.3 ..."

Published: Mar 12th, 2021 5:00 PM

UK conditionally approves Lilly's Retsevmo

"... advanced RET mutant medullary thyroid cancer (MTC) who require systemic therapy following prior treatment with cabozantinib and/or vandetanib."

Published: Mar 12th, 2021 2:04 AM

C4 Therapeutics Reports Recent Business Highlights and Full Year 2020 Financial Results

"... for the treatment of solid tumors, including relapsed or refractory NSCLC and sporadic medullary thyroid cancers that are resistant to RET inhibitors."

Published: Mar 11th, 2021 2:33 AM

Lilly Announces Details of Presentations at 2021 American Association for Cancer Research (AACR)

"... will highlight safety and efficacy data of Retevmo (selpercatinib) in the treatment of RET fusion-positive cancers outside of lung and thyroid cancer."

Published: Mar 10th, 2021 9:53 PM

Brain Tumor Market is Projected to Propel Humbly at a CAGR of 4.19% in the 7MM for the Study ...

"... therapies, VAL-083 and Durvalumab target unmethylated MGMT form of glioblastoma while ONC201 targets H3 K27M-mutant form of glioma."

Published: Mar 9th, 2021 6:07 PM

GI symptoms negatively affect quality of life in multiple endocrine neoplasia type 2

"The MEN2B cohort had more than double the prevalence of severe to very severe abdominal cramps (35% vs. 15%) and severe bloating (50% vs. 22%) ..."

Published: Mar 6th, 2021 4:15 AM

Blueprint Medicines Corp (BPMC) CEO and President Jeffrey W. Albers Sold $1.7 million of Shares

"Its drug candidates include avapritinib, BLU 554, BLU-782 and BLU-667. Blueprint Medicines Corp has a market cap of $5.56 billion; its shares were ..."

Published: Mar 4th, 2021 7:15 PM

Turning Point Therapeutics to Participate in Upcoming Investor Conferences

"... being studied in a Phase 1 trial of patients with advanced or metastatic solid tumors harboring genetic alterations in MET; TPX-0046, targeting RET, ..."

Published: Mar 4th, 2021 2:00 AM

BlossomHill Therapeutics Closes $71M Series A Financing

"... compounds which include Crizotinib, Lorlatinib, Repotrectinib (TPX-0005), TPX-0022, TPX-0046, and TPX-0131. Contact: info@bhtherapeutics.com."

Published: Mar 2nd, 2021 2:56 PM

Guest Opinion: The FDA can help patients with rare diseases

"The FDA approved the first parathyroid hormone therapy called Natpara as an adjunct therapy for hypoparathyroidism to be used with supplements."

Published: Mar 2nd, 2021 4:26 AM

Thyroid cancer incidence trends by histology in 25 countries: a population-based study

"Temporal trends for follicular and medullary thyroid cancer did not show consistent patterns across countries, but slight decreases were seen for ..."

Published: Feb 27th, 2021 1:48 AM

A Decade of Thyroid Cancer Research Brings Precision Medicine to the Forefront of Care

"The rising prevalence of thyroid cancer and thyroid nodules, especially for differentiated thyroid cancer (DTC), has ... mutations in medullary thyroid cancer and RET fusions in radioactive iodine (RAI)refractory differentiated thyroid ..."

Published: Feb 16th, 2021 9:41 PM

What Is a Hypoechoic Thyroid Nodule?

"In these cases, the nodule is caused by irregular cell growth associated with the cancer. One type of thyroid cancer-medullary thyroid cancer-is ..."

Published: Feb 15th, 2021 11:33 AM

Chimerix: Recent Acquisition Gives This Laggard Antiviral Company A Fresh Start In Oncology

"ONC201. This molecule has seen unprecedented single agent activity in recurrent H3 K27M mutant glioma, which currently has no effective therapy. The ..."

Published: Feb 12th, 2021 12:07 AM

Exelixis' (EXEL) Q4 Earnings Surpass Estimates, Sales Miss

"... of medullary thyroid cancer generated $4 million in net product revenues. ... with Roche's RHHBY Tecentriq in patients with advanced solid tumors."

Published: Feb 10th, 2021 3:30 AM

Tmunity expands T-cell engineered therapies partnership with Penn.

"February 9, 2021 -- Tmunity Therapeutics said it has expanded its T-cell engineered therapy collaboration with the University of Pennsylvania."

Published: Feb 10th, 2021 12:41 AM

Bob Sanders | The FDA can help patients with rare diseases

"The FDA approved the first parathyroid hormone therapy - called Natpara - as an adjunct therapy for hypoparathyroidism to be used with ..."

Published: Feb 8th, 2021 9:06 PM

Exelixis (EXEL) to Report Q4 Earnings: What's in the Cards?

"... carcinoma (RCC) and previously treated hepatocellular carcinoma (HCC), ... capsules) is approved for the treatment of medullary thyroid cancer."

Published: Feb 8th, 2021 2:00 PM

How Much Do You Know About Your Thyroid?

"As important as the thyroid gland is, it's quite clear that many of us are ... There are four different types of thyroid cancers, with medullary being the ..."

Published: Feb 5th, 2021 10:05 PM

Pralsetinib Approval Expands Options for RET-Positive Thyroid Cancers

"... metastatic RET-mutant medullary thyroid cancer (MTC) who require systemic therapy and those with RET fusion positive thyroid cancer who need ..."

Published: Feb 5th, 2021 10:03 PM

Pralsetinib Approval Expands Options for RET-Positive Thyroid Cancers

"The FDA granted accelerated approval to pralsetinib (Gavreto) on December 1, 2020, for patients 12 years and older with advanced or metastatic RET- ..."

Published: Feb 5th, 2021 3:41 AM

EGFR/RET TKI Combination Active Against EGFR+ NSCLC With Acquired RET Fusion

"The combination of osimertinib and selpercatinib was found to be an active regimen in patients with EGFR-positive nonsmall cell lung cancer with ..."

Published: Feb 5th, 2021 2:11 AM

Multikinase Inhibitor Options Flourish for Patients With RET-Mutant Medullary Thyroid Cancer

"A few rules of thumb: When medullary thyroid cancer presents as a palpable nodule-if it presents as a palpable nodule and that's when you're ..."

Published: Feb 4th, 2021 9:02 PM

2020 Approvals Expand Access to Care for Patients Across Tumor Types

"... for patients harboring RET mutations and for patients with indications that include medullary thyroid cancer (MTC).¹. Approvals in other rare cancers ..."

Published: Feb 4th, 2021 3:07 AM

Trial Results Show Patients With RET Alterations Experience Different Efficacy With Lung Cancer ...

"RET fusions [are found] in anaplastic thyroid cancer, papillary thyroid cancer, and other nonmedullary thyroid cancers, [as well as] in lung ..."

Published: Feb 1st, 2021 8:45 PM

RET Joins the Ranks of Actionable Targets in Precision Oncology

"RET alterations occur infrequently outside of thyroid cancer. ... of medullary thyroid cancer (MTC), RET mutations subsequently have been identified in ..."

Published: Feb 1st, 2021 1:25 PM

Regulator designated 2 more orphan drugs

"... metastatic non-small cell lung cancer, medullary thyroid cancer and thyroid carcinoma, and idecabtagene vicleucel that treats multiple myeloma."

Published: Jan 28th, 2021 7:24 AM

CStone Pharmaceuticals Reports Efficacy and Safety Data from the ARROW Trial of Pralsetinib in ...

"These results mark the first medical conference presentation of data for pralsetinib in Chinese patients with RET fusion-positive NSCLC previously ..."

Published: Jan 28th, 2021 7:15 AM

CStone Pharmaceuticals Reports Efficacy and Safety Data from the ARROW Trial of Pralsetinib in ...

"... RET fusion-positive NSCLC, RET-mutant medullary thyroid cancer (MTC) and other advanced solid tumors with RET fusions. Data from the ARROW ..."

Published: Jan 25th, 2021 8:29 PM

News briefing: Jeffrey Leiden to chair Tmunity board of directors; Opdivo wins new approval in ...

"Tmunity is currently evaluating its T-cell engineering approaches in the clinic with three programs. The first targets metastatic castrate resistant ..."

Published: Jan 21st, 2021 3:18 AM

Selpercatinib Safe, Effective for Medullary Thyroid Cancer With RET Mutation

"A phase 1/2 trial found Selpercatinib to be effective, with manageable safety, in patients with RET-mutant medullary thyroid cancer, both with or without ..."

Published: Jan 19th, 2021 8:45 PM

Lilly, Merus Ink Up-to-$1.6B Bispecific Antibody Partnership vs. Cancer

"... RET inhibitor indicated for forms of non-small cell lung cancer, medullary thyroid cancer, and other types of thyroid cancers in patients whose tumors ..."

Published: Jan 18th, 2021 7:03 PM

Larotrectinib Excites Landscape for TRK Fusion-Positive Thyroid Cancers

"RET fusions are seen in papillary, poorly differentiated and anaplastic thyroid cancers and RET mutations are seen in medullary thyroid cancer."

Published: Jan 17th, 2021 1:03 AM

Dr. Subbiah on the Clinical Activity of Pralsetinib in RET+ Cholangiocarcinoma

"Vivek Subbiah, MD, of The University of Texas MD Anderson Cancer Center, discusses the clinical activity of pralsetinib (Gavreto) in RET fusion-positive ..."

Published: Jan 16th, 2021 3:30 AM

Despite the challenges brought with the coronavirus disease (COVID-19) pandemic, 2020 was ...

"New Treatments for Non-Small Cell Lung Cancer. The U.S. Food and Drug Administration (FDA) recently approved Retevmo (selpercatinib) as the first ..."

Published: Jan 15th, 2021 4:48 AM

Selpercatinib Effective Therapy for RET Fusion-Positive Non-Small Cell Lung Cancer

"... in patients with RET fusion-positive solid tumors and RET-mutant medullary thyroid cancer. About half of the patients enrolled on the trial have RET ..."

Published: Jan 13th, 2021 8:45 AM

High risk thyroid nodule discrimination and management by modified TI-RADS

"Thyroid papillary carcinoma was found in all patients, with the exception of one thyroid medullary carcinoma. In thyroid benign and malignant nodule ..."

Published: Jan 12th, 2021 3:41 AM

New Developments in Thyroid Cancer

"This drug is approved for RET-altered thyroid cancers, namely RET-mutated medullary thyroid cancers and RET fusions in radioactive iodine ..."

Published: Jan 8th, 2021 3:52 PM

Chimerix Acquires Oncoceutics to Expand Pipeline with Late-Stage Oncology Program

"ONC201 Registrational Trial for Recurrent H3 K27M-mutant Glioma. Compelling Response Rates to Date; Defined Regulatory Path to Registration."

Published: Jan 7th, 2021 4:48 PM

Thyroid cancer: In-utero exposures can increase your risk of this disease

"Certain genetic health conditions like familial medullary thyroid cancer, multiple endocrine neoplasia, Cowden's syndrome and familial adenomatous ..."

Published: Jan 6th, 2021 11:33 PM

New Drug Gives Young Thyroid Cancer Patient a Second Chance at Life

"The FDA approved pralsetinib (Gavreto), a selective RET-inhibitor drug, for RET fusion-positive non-small cell lung cancers (NSCLC) on September 4, ..."

Published: Jan 6th, 2021 2:22 AM

Tmunity to Present at the 39th Annual JP Morgan Healthcare Conference

"Tmunity Therapeutics, Inc., a private clinical-stage biotherapeutics company focused on saving and improving lives by delivering the full potential of ..."

Published: Jan 4th, 2021 4:03 PM

New drug approvals hit a high note in 2020 but face uncertainty in 2021

"Along with Gavreto, Blueprint got a nod for Ayvakit in gastrointestinal stromal tumors, a rare cancer that occurs in the stomach or small intestine. Acacia ..."

Published: Dec 30th, 2020 7:15 AM

New Approved Treatments and Indications in Oncology

"... nonsmall-cell lung cancer (NSCLC) and advanced thyroid cancers. ... metastatic RET-mutant medullary thyroid cancer requiring systemic therapy, ..."

Published: Dec 29th, 2020 5:00 AM

The Top 10 FDA Oncology Drug Approvals of 2020

"... cell lung cancer (NSCLC), medullary thyroid cancer and other types of thyroid cancers with rearranged during transfection, or RET, alterations."

Published: Dec 29th, 2020 3:52 AM

7 recent drug, device approvals

"Roche & Blueprint Medicines' Gavreto - The FDA Dec. 2 approved Gavreto, a drug developed by Roche and Blueprint Medicines, to treat patients 12 ..."

Published: Dec 24th, 2020 2:11 PM

EMA adopts positive opinions for breast, lung, GU cancer indications

"... opinion for use in patients with RET fusion-positive advanced NSCLC, as well as those with medullary thyroid or thyroid cancer with RET alterations."

Published: Dec 24th, 2020 2:20 AM

Bring back Natpara: FDA must help hypoparathyroidism sufferers

"Bring back Natpara: FDA must help hypoparathyroidism sufferers. Agency must show the same urgency for these Americans that it shows for treatment of ..."

Published: Dec 24th, 2020 1:48 AM

Experts Reflect on Most Impactful FDA Moves of 2020 in Solid Tumors, Hematologic Malignancies

"... and pediatric patients 12 years of age and older with advanced or metastatic RET-mutant medullary thyroid cancer who require systemic therapy, ..."

Published: Dec 23rd, 2020 10:03 PM

Types of Thyroid Cancer

"Types of Thyroid Cancer · Differentiated · Medullary Thyroid Cancer (MTC) · Anaplastic Thyroid Cancer · Less Common Types of Thyroid Cancers · A Word ..."

Published: Dec 22nd, 2020 12:38 AM

Blueprint Medicines (BPMC) Rises 40% in Past 3 Months: Here's Why

"Gavreto is a once-daily oral precision therapy that selectively inhibits RET-altered cancers. In September 2020, the FDA approved Gavreto for the ..."

Published: Dec 18th, 2020 4:37 PM

Parathyroid Hormone Global Market Report 2020-30: COVID-19 Growth and Change

"It also adds the rights of parathyroid hormone NATPARA. Shire Plc is a US-based pharmaceutical company focusing on innovative and rare disease ..."

Published: Dec 17th, 2020 3:52 PM

Oncoceutics out-licenses ONC201 for Greater China to CR Sanjiu

""We are thrilled to form this partnership with CR Sanjiu whose dedication to innovative therapies and make them the ideal collaborators to bring ONC201 ..."

Published: Dec 17th, 2020 3:25 AM

Blueprint Medicines Corp (BPMC) CEO and President Jeffrey W. Albers Sold $595900 of Shares

"Its drug candidates include avapritinib, BLU 554, BLU-782 and BLU-667. Blueprint Medicines Corp has a market cap of $6.54 billion; its shares were ..."

Published: Dec 14th, 2020 8:00 PM

EMA Panel Endorses Approval of Five New Cancer Drugs

"These cancers include RET-fusion-positive nonsmall cell lung cancer (NSCLC), RET-fusion-positive thyroid cancer, and RET-mutant medullary ..."

Published: Dec 11th, 2020 9:30 PM

News anchor set to have 'cancerous' tumour removed after eagle-eyed viewers spot strange ...

"Its presence is usually indicated by a swelling in the neck. There are four main types: papillary thyroid cancer, follicular thyroid cancer, medullary thyroid ..."

Published: Dec 11th, 2020 9:18 PM

Bumper crop of novel meds backed for approval by EMA's CHMP

"... (RET) gene fusion: RET-fusion positive non-small cell lung cancer, RET-fusion positive thyroid cancer and RET-mutant medullary-thyroid cancer."

Published: Dec 10th, 2020 5:33 AM

CStone's Partner Blueprint Medicines Announces US FDA Approval of GAVRETO (pralsetinib) for ...

"Expands GAVRETO label following initial approval for RET fusion-positive non-small cell lung cancer in September 2020 --. SUZHOU, China, Dec."

Published: Dec 9th, 2020 6:07 PM

Tmunity to Present at the 2020 RBC Capital Markets Healthcare Private Company Conference

"Tmunity Therapeutics, Inc., a private clinical-stage biotherapeutics company focused on saving and improving lives by delivering the full potential of ..."

Published: Dec 7th, 2020 3:07 PM

ASH: Lilly builds case for its BTK drug LOXO-305 in lymphoma

"If it eventually does get approved, LOXO-305 would join Lilly's RET inhibitor Retevmo (selpercatinib, formerly LOXO-292) on the market, becoming the ..."

Published: Dec 5th, 2020 10:18 PM

Why Is Exelixis (EXEL) Down 14.4% Since Last Earnings Report?

"Cometriq (cabozantinib capsules) for the treatment of medullary thyroid cancer generated $9 million in net product revenues. Exelixis earned $19.9 ..."

Published: Dec 5th, 2020 12:07 AM

Creating central Ohio connections in the fight against cancer

"Jane had just recovered from her own bout of cancer (medullary thyroid cancer) and while attending a cancer support forum, she and Kevin were ..."

Published: Dec 4th, 2020 11:56 PM

Trending News on Targeted Oncology, Week of December 4, 2020

"... and pediatric patients who are 12 years old or older with advanced or metastatic RET-mutant medullary thyroid cancer and require systemic therapy."

Published: Dec 4th, 2020 2:45 PM

Genentech's Gavreto scores US approval for RET thyroid cancer

"Roche's Genentech division and its partner Blueprint Medicines have scored a new approval for Gavreto in the US for the treatment of RET-altered ..."

Published: Dec 4th, 2020 5:45 AM

Gavreto Approved for Treatment of RET-Altered Thyroid Cancers

"... Genentech/Blueprint Medicines) for patients aged 12 years and older with advanced or metastatic RET-mutant medullary thyroid cancer (MTC) who ..."

Published: Dec 3rd, 2020 8:22 PM

Gavreto Gets Accelerated Approval for RET-Altered Thyroid Cancers

"... RET-mutant medullary thyroid cancer (MTC) who require systemic therapy, or with RET fusion-positive thyroid cancer who require systemic therapy ..."

Published: Dec 3rd, 2020 2:33 AM

FDA Approvals Roundup: Imcivree, Danyelza, Ga 68 PSMA-11

"Gavreto gets expanded indications for RET-altered thyroid cancers. Blueprint Medicines' Gavreto (pralsetinib capsules) has received two new ..."

Published: Dec 3rd, 2020 1:13 AM

Genentech, Blueprint Medicine's Gavreto Receives FDA Approval in RET-Altered Thyroid Cancer

"... second precision medicine option for patients with these types of cancers, following the FDA's approval of selpercatinib (Eli Lilly's Retevmo) in May."

Published: Dec 2nd, 2020 9:54 PM

Roche, Blueprint catch up with Lilly as Gavreto snags FDA thyroid cancer nod

"The FDA has approved Roche and Blueprint Medicines' Gavreto in advanced or metastatic RET-mutant medullary or RET fusion-positive thyroid ..."

Published: Dec 2nd, 2020 8:19 PM

Roche turns up the heat on Lilly with another Gavreto approval, elbowing its way into the thyroid ...

"Max Gelman. Associate Editor. Roche and Blueprint Medicines are continuing to put pressure on rivals Eli Lilly and Loxo, as their Gavreto drug ..."

Published: Dec 2nd, 2020 4:37 PM

Roche, Blueprint raise pressure on Lilly with new Gavreto approval

"Retevmo (selpercatinib) was simultaneously approved by the agency for the lung and thyroid cancer in May, so has enjoyed an all-too brief period as ..."

Published: Dec 2nd, 2020 3:52 AM

FDA Approves Pralsetinib for Thyroid Cancers Harboring RET Alterations

"On December 1, 2020, the FDA granted approval to pralsetinib (Gavreto, Blueprint Medicines Corporation) for patients with advanced or metastatic ..."

Published: Dec 2nd, 2020 2:22 AM

FDA approves Gavreto for RET-altered thyroid cancers

"Source: Adobe Stock. Pralsetinib (Gavreto, Blueprint Medicines) is a once-daily oral therapy designed to target oncogenic RET alterations. The FDA ..."

Published: Dec 2nd, 2020 1:48 AM

Genentech Announces FDA Approval of Gavreto (pralsetinib) for People With Advanced or ...

"Tumor Lysis Syndrome (TLS): Cases of TLS have been reported in patients with medullary thyroid carcinoma receiving Gavreto. Patients may be at risk ..."

Published: Dec 2nd, 2020 1:26 AM

FDA OKs Blueprint Medicines and Roche's Gavreto for type of medullary thyroid cancer

"Blueprint Medicines (BPMC -2.5%) and collaboration partner Roche (OTCQX:RHHBY +2.1%) announce the FDA nod for Gavreto (pralsetinib) for the ..."

Published: Dec 1st, 2020 11:20 PM

November UKG Workforce Activity Report: Smaller Businesses Lose Shifts

"Approximately 10-20% of people with papillary thyroid cancer (the most ... RET-mutant medullary thyroid cancer (MTC), RET fusion-positive thyroid ..."

Published: Dec 1st, 2020 3:30 AM

Cabozantinib for Prostate Cancer - A Renewed Hope

"... hepatocellular carcinoma,⁵ and medullary thyroid cancer,⁶ enthusiasm for single-agent use in prostate cancer was lost after the above experience."

Published: Nov 30th, 2020 3:50 PM

Adrenocortical Carcinoma Pipeline, Emerging Therapies and Key Players by DelveInsight

"Cabozantinib is already approved by the US FDA for the treatment of metastatic medullary thyroid cancer, advanced renal cell carcinoma with history ..."

Published: Nov 25th, 2020 9:30 PM

Multikinase Inhibitor Options Abound for Patients With RET-Mutant Medullary Thyroid Cancer

"RET aberrations in medullary [thyroid cancer are] mostly point mutations. In papillary thyroid cancer, you can still have point mutations, but it's mostly ..."

Published: Nov 23rd, 2020 7:48 PM

Catalent, Blueprint Enter GAVRETO Commercial Supply Pact

"GAVRETO is a new therapy developed by Blueprint Medicines for the treatment of metastatic RET fusion-positive non-small cell lung cancer (NSCLC) as ..."

Published: Nov 23rd, 2020 7:02 PM

Catalent Signs Commercial Supply Agreement with Blueprint Medicines Following FDA Approval ...

"Catalent Signs Commercial Supply Agreement with Blueprint Medicines Following FDA Approval of GAVRETO (pralsetinib) ..."

Published: Nov 20th, 2020 7:01 PM

'What you see here now, this is my wife. It feels like we've got her back': Middlesbrough coach ...

"Gemma, 40, was given 12 months to live last year but her brain tumour is now 'stable' after use of a trial drug from Germany; ONC201 costs 5,000 per ..."

Published: Nov 20th, 2020 12:18 AM

Real-World Date Confirm Vandetanib and Cabozantinib Are Effective 1L/2L Treatments for ...

"For the majority of patients with medullary thyroid cancer (MTC), vandetanib (Caprelsa) and cabozantinib (Cabometyx) are both effective treatment ..."

Published: Nov 19th, 2020 9:36 PM

Interesting WRB Put And Call Options For July 2021

"Gavreto is a once-daily, oral precision therapy designed to selectively target RET alterations, including fusions and mutations. The approval is for the ..."

Published: Nov 12th, 2020 10:48 PM

Cabozantinib Plus Pembrolizumab May Improve Melanoma Outcomes

"... such as renal cell carcinoma, hepatocellular carcinoma, and medullary thyroid cancer. c-MET activation promotes PD-L1 expression, noted Jain."

Published: Nov 12th, 2020 9:52 PM

Objective Responses Observed in Rare Thyroid Tumors With Dual Checkpoint Blockade

"The most common thyroid cancer subtype was papillary in 47% of patients, while other subtypes in the cohort included medullary thyroid cancer (MTC; ..."

Published: Nov 6th, 2020 9:18 PM

Exelixis' (EXEL) Q3 Loss Wider Than Expected, Revenues Beat

"Cometriq (cabozantinib capsules) for the treatment of medullary thyroid cancer generated $9 million in net product revenues. Exelixis earned $19.9 ..."

Published: Nov 6th, 2020 2:00 AM

Tmunity to Present at Upcoming Investor Conferences

"Tmunity Therapeutics, Inc., a private clinical-stage biotherapeutics company focused on saving and improving lives by delivering the full potential of ..."

Published: Nov 6th, 2020 12:30 AM

Roles of the RET Proto-oncogene in Cancer and Development

"Moreover, point mutations in RET are responsible for multiple endocrine neoplasia types 2A and 2B, which can develop into medullary thyroid cancer ..."

Published: Oct 31st, 2020 12:07 AM

NIH Starts Clinical Trial with ONC206, a Next-Generation Imipridone

"While DRD2 is also targeted by ONC201, ONC206 exhibits distinct biological effects and chemical properties that position its clinical development in ..."

Published: Oct 29th, 2020 8:56 PM

Blueprint Medicines (BPMC) Q3 Earnings Beat, Revenues Rise Y/Y

"... with various types of RET-altered thyroid cancers and other solid tumors. ... medullary thyroid cancer (MTC) and RET fusion-positive thyroid cancer."

Published: Oct 27th, 2020 7:03 PM

Pralsetinib and Selpercatinib Expand the RET+ NSCLC Paradigm

"Justin F. Gainor, MD, discusses the recent FDA approvals of pralsetinib and selpercatinib, which led to expanded treatment options for patients with non ..."

Published: Oct 27th, 2020 3:49 PM

Lilly Reports Third-Quarter Financial Results, Updates Guidance

"... Verzenio, Jardiance, Olumiant, Emgality, Tyvyt, Baqsimi, Cyramza, Retevmo and Basaglar contributed nearly 9 percentage points of revenue growth ..."

Published: Oct 26th, 2020 8:56 PM

Triple meeting the point of turning to TPX-0022

"However, TPX-0022 hits two additional kinases involved in tumour ... assets Turning Point is now highlighting include TPX-0046, a Ret inhibitor to rival ..."

Published: Oct 24th, 2020 7:15 PM

Turning Point Therapeutics Announces Pricing of $400 Million Public Offering of Common Stock

"... a Phase 1 study called SHIELD-1 in patients with advanced or metastatic solid tumors harboring genetic alterations in MET; RET inhibitor TPX-0046, ..."

Published: Oct 24th, 2020 2:00 PM

Thyroid cancer: Cushing syndrome is a lesser-known warning sign what is it?

""Medullary carcinoma of the thyroid is also probably related to this group of tumours. It is suggested that the great majority of the tumours associated with ..."

Published: Oct 23rd, 2020 1:25 AM

Pralsetinib

"Pralsetinib is a kinase inhibitor indicated for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion- positive non- ..."

Published: Oct 19th, 2020 5:11 PM

Orphan Drugs Market to Witness Massive Growth by 2027 | Top Players Hoffmann-La Roche Ltd ...

"... Gaucher disease type 1 (GD1), Metastatic medullary thyroid carcinoma, Advanced gastric cancer or gastro-esophageal junction adenocarcinoma, ..."

Published: Oct 19th, 2020 1:03 AM

VIDEO: Surgeon shares pearls for new drug delivery options

"Blueprint's Positive Pralsetinib Data Places New Option on Horizon for RET-Altered Cancer Patients. Precision Oncology News, 2020. Single-Cell ..."

Published: Oct 19th, 2020 12:30 AM

Hunting Resistance Mechanisms in RET-Fusion Lung Cancer

"Pralsetinib is a potent and selective TKI that targets RET alterations, which drive roughly 1%-2% of NSCLC cases, and was designed to have limited ..."

Published: Oct 15th, 2020 11:45 PM

TRK Fusions Help to Fulfill Unmet Need in Thyroid Cancer Treatment Landscape

"TRK fusions have not been observed in medullary thyroid cancer, however, limiting use of larotrectinib (Vitrakvi), a TRK inhibitor, to patients with DTC ..."

Published: Oct 15th, 2020 9:07 PM

A Phase II Study of Cabozantinib, Nivolumab, and Ipilimumab Immunotherapy in Patients with ...

"Cabozantinib inhibits an enzyme called tyrosine kinase which can fuel cancer growth; it is already used to treat medullary thyroid cancer. Nivolumab ..."

Published: Oct 15th, 2020 6:18 PM

Endocrine Update 2021 - LIVESTREAM

"... medullary thyroid cancer; current and recently approved systemic treatment ... of bone loss after bariatric surgery to prevent metabolic bone disease."

Published: Oct 14th, 2020 7:48 PM

RET Inhibitor Enters the Therapeutic Ring in Multiple Settings

"Selpercatinib (Retevmo) joins the ranks of therapies approved for several tumor types, with indications for patients with nonsmall cell lung cancer ..."

Published: Oct 14th, 2020 5:56 PM

ESMO Data Show Benefit of Approved Thyroid Cancer Regimens in Select Patients

"The key takeaway from these data were that testing for NTRK gene fusions should be routine for patients with non-medullary, advanced thyroid cancer ..."

Published: Oct 13th, 2020 9:07 PM

Selpercatinib Data Underscore Value of Precision Medicine in RET-Driven Lung Cancer

"The LIBRETTO-001 study demonstrated promising activity with selpercatinib, the selective RET inhibitor, as treatment of patients with RET-mutant ..."

Published: Oct 13th, 2020 5:17 PM

Hainan's Lecheng begins to sell top-notch US cancer drug

"According to the news outlet, the drug is called pralsetinib and it is extremely effective in the treatment of non-small cell lung cancer. The Food and ..."

Published: Oct 13th, 2020 4:37 AM

YOUR HEALTH: One young man saved from a rare cancer

"Tanner had stage four medullary thyroid cancer. Doctors tried every treatment available but nothing worked. "It was going to be hospice," said Cleveland ..."

Published: Oct 13th, 2020 2:33 AM

Patient-Reported Outcomes Confirm Tolerability of Selpercatinib in RET-Driven Thyroid Cancer

"... with RET-altered medullary thyroid cancer (MTC) or advanced thyroid cancer. These findings ultimately led to the FDA approval of this RET inhibitor, ..."

Published: Oct 9th, 2020 10:41 PM

Teacher who was diagnosed with thyroid cancer at age 21 and had 100 tumors in her lungs - but ...

"An ultrasound led to a diagnosis of medullary thyroid cancer. Doctors then performed surgery to remove her thyroid and 42 lymph nodes. Ashley Wyss ..."

Published: Oct 9th, 2020 1:26 PM

Teacher with 100 cancerous tumours in her lungs who refused to live in fear dies

""She will be remembered for her positivity, kindness, and strength during her nine-year battle with medullary thyroid cancer. A tumour resulted in Ashley ..."

Published: Oct 8th, 2020 1:26 AM

Immune co-inhibitory receptors PD-1, CTLA-4, TIM-3, LAG-3 and TIGIT in medullary thyroid ...

"Researchers analyzed a large cohort of medullary thyroid carcinomas ... coexpression were identified as promising biomarkers for tumor recurrence, ..."

Published: Oct 7th, 2020 5:33 PM

Cancer is Still the Real Global Health Crisis Four Stocks with Answers (EXEL, BMY, NBIO, MRK)

"... the treatment of patients with progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, ..."

Published: Oct 6th, 2020 6:07 PM

Selpercatinib Induces Infrequent Hypersensitivity in RET Fusion-Positive NSCLC, Analysis Shows

"Selpercatinib (LOXO-292)-related hypersensitivity reactions occurred infrequently in patients with RET fusion-positive nonsmall cell lung cancer ..."

Published: Oct 3rd, 2020 2:24 AM

Untargeted longitudinal analysis of a wellness cohort identifies markers of metastatic cancer years ...

"CALCA, a biomarker for medullary thyroid cancer, was hypersecreted in metastatic pancreatic cancer at least 16.5 months pre-diagnosis. ERBB2 ..."

Published: Oct 2nd, 2020 11:56 PM

A Look Back at the FDA News from September 2020

"... of patients with advanced or metastatic RET-mutant medullary thyroid cancer as well as for patients with RET fusionpositive thyroid cancer."

Published: Oct 2nd, 2020 6:30 PM

US FDA approval tracker: September

"Roche will co-commercialise Gavreto with Blueprint in the US after paying $650m up front for rights. Elsewhere, Glaxosnithkline's Nucala became the ..."

Published: Oct 1st, 2020 8:33 PM

Fast Five Quiz: Thyroid Cancer Practice Essentials

"Most thyroid cancers are papillary carcinomas, with follicular carcinomas, medullary thyroid carcinomas, and anaplastic carcinomas accounting for far ..."

Published: Oct 1st, 2020 8:00 PM

NSCLC Treatment Portfolio Gains RET-Targeted Therapy

"Results showed that pralsetinib elicited durable responses, with 57% and 70% of patients with previously treated and treatment-nave disease ..."

Published: Sep 30th, 2020 6:07 PM

Turning Point Therapeutics to Participate in Upcoming Virtual Investor Conference

"... patients with advanced or metastatic solid tumors harboring genetic alterations in MET; TPX-0046, targeting RET and SRC, which is being studied in ..."

Published: Sep 29th, 2020 10:37 PM

10 recent exec moves affecting the pharma industry

"Philadelphia-based drugmaker Tmunity named Johnson & Johnson and GlaxoSmithKline veteran Vijay Reddy, MD, its new chief research and ..."

Published: Sep 29th, 2020 9:28 PM

Blueprint Medicines Rises YTD on Robust Ayvakit Progress

"Both companies will co-commercialize Gavreto in the United States while Roche alone will commercialize the drug outside the United States. Story ..."

Published: Sep 29th, 2020 9:18 PM

Blueprint Medicines Rises YTD on Robust Ayvakit Progress

"Further, the FDA granted a Priority Review to Gavreto for the treatment of advanced/metastatic RET-mutant medullary thyroid cancer (MTC) and RET ..."

Published: Sep 29th, 2020 7:48 PM

The window of opportunity opens wider for Ascendis

"This aims to overcome Natpara's problem variable PTH levels; Natpara was also associated with calcium imbalances, and carried a black box ..."

Published: Sep 28th, 2020 7:55 PM

Clinical trial of selpercatinib shows strong response for patients with non-small cell lung cancer

"... medullary thyroid cancer who require systemic therapy, and c) patients 12 and older with advanced or metastatic RET-fusion positive thyroid cancer ..."

Published: Sep 28th, 2020 7:15 PM

Clinical trial of selpercatinib shows strong response for patients with non-small cell lung cancer

"Singapore, 28 September 2020 - An international team of researchers has found that selpercatinib, a drug that precisely targets cancers driven by ..."

Published: Sep 28th, 2020 5:33 PM

Targeted therapy found to be effective at shrinking tumors in patients with nonsmall-cell lung cancer

"... lung cancer, b) adults and children 12 and older, with advanced or metastatic RET-mutated medullary thyroid cancer who require systemic therapy, ..."

Published: Sep 28th, 2020 5:02 PM

Clinical Trial of Selpercatinib Shows Strong Response for Patients with Non-Small Cell Lung Cancer

"Singapore, 28 September 2020 An international team of researchers has found that selpercatinib, a drug that precisely targets cancers driven by ..."

Published: Sep 27th, 2020 12:41 AM

Tmunity to Present at Upcoming Investor Conferences

"Tmunity Therapeutics, Inc., a private clinical-stage biotherapeutics company focused on saving and improving lives by delivering the full potential of ..."

Published: Sep 26th, 2020 2:11 AM

Healthy Living: Retevmo for Thyroid Cancer

"... in May for people with non-small cell lung cancer, and two types of thyroid cancer with specific gene mutations, including medullary thyroid cancer."

Published: Sep 24th, 2020 7:15 PM

Study: Pralsentinib May Be an Effective Treatment for RET Mutation-Positive Medullary Thyroid ...

"Pralsetinib (BLU-667) shows promise as an effective treatment for patients with advanced RET mutation-positive medullary thyroid cancer (MTC), ..."

Published: Sep 23rd, 2020 7:48 PM

Gavreto (pralsetinib) for the Treatment of Non-Small Cell Lung Cancer (NSCLC)

"Gavreto (pralsetinib) is a targeted therapy indicated for the treatment of metastatic rearranged during transfection (RET) fusion-positive non-small ..."

Published: Sep 23rd, 2020 4:48 AM

Positive top-line data drive Blueprint toward an sNDA

"This rare disease is often undiagnosed or misdiagnosed, according to ... in RETm medullary thyroid cancer and RET fusion-positive thyroid cancer by ..."

Published: Sep 21st, 2020 11:11 PM

Larotrectinib Induces Promising Response Rate in Patients With Differentiated Thyroid Cancer

"These findings indicate that routine testing for NTRK gene fusions should be considered in patients with non-medullary advanced thyroid cancer as this ..."

Published: Sep 21st, 2020 8:22 PM

Blueprint Medicines says durable clinical benefits observed for Gavreto in thyroid cancer

"GAVRETO was well-tolerated, and overall, treatment-related adverse events were primarily mild to moderate. Investigator-reported serious/servere ..."

Published: Sep 21st, 2020 5:00 PM

Thyroid Cancer: Small Gland, Big Impact

"There are four main types of thyroid cancer (papillary, follicular, medullary and anaplastic). Luckily, most types of thyroid cancer are very treatable and ..."

Published: Sep 21st, 2020 2:22 AM

Ongoing ARROW Trial Data Support Pralsetinib as a Potential Treatment Option in RET-Mutant MTC

"Patients with medullary thyroid cancer (MTC) harboring abberations in RET who were treated with pralsetinib (Gavreto) across therapy lines exhibited ..."

Published: Sep 21st, 2020 12:41 AM

Pralsetinib Active in RET-Mutant Advanced Medullary Thyroid Cancer

"Potent and durable clinical activity was shown with pralsetinib (Gavreto) as treatment of patients with RET-mutant advanced medullary thyroid cancer ..."

Published: Sep 20th, 2020 2:00 PM

Progress in treating medullary thyroid cancer

"Recently, there has been tremendous progress made in treating this disease with targeted therapy. We recently spoke with Mimi Hu, M.D., to learn more..."

Published: Sep 18th, 2020 10:37 PM

Turning Point Therapeutics to Participate in HC Wainwright Precision Oncology Investor Conference

"... TPX-0046, targeting RET and SRC, which is being studied in a Phase 1/2 trial of patients with advanced or metastatic solid tumors harboring genetic ..."

Published: Sep 16th, 2020 6:18 PM

Best Life: New drug controls rare cancers with gene mutation

"But for those with medullary thyroid cancer, a rare form of the disease, there have been few effective options. Now, introducing the first young man in ..."

Published: Sep 16th, 2020 2:14 AM

Selpercatinib

"Reduce selpercatinib dose in patients with severe hepatic impairment. Consult manufacturer's labeling for recommended dosage modifications for ..."

Published: Sep 15th, 2020 2:56 AM

From natural killer cells to off-the-shelf CAR-Ts, biopharma targets cancer with next-gen cell ...

"This month, Tmunity Therapeutics expects to finish enrolling an early clinical trial testing an engineered CAR-T immune cell therapy for metastatic ..."

Published: Sep 15th, 2020 2:00 AM

Benefits and limitations of TKIs in patients with medullary thyroid cancer: A systematic review and ...

"... meta-analysis, researchers documented clinical response and toxicities of tyrosine kinase inhibitors (TKIs) in advanced medullary thyroid carcinoma ..."

Published: Sep 13th, 2020 4:47 PM

Data Shows That Workers Are Waiting Much Too Long to Start Saving for Retirement

"... of proteins known to drive aggressive tumor growth for around 1% to 2% of all cases of NSCLC, and around 60% of all medullary thyroid cancers."

Published: Sep 13th, 2020 4:37 PM

Is Blueprint Medicines a Good Biotech Stock to Buy Now?

"... and around 60% of all medullary thyroid cancers. In a clinical trial leading to its approval, Gavreto shrank tumors for 70% of treatment-naive NSCLC ..."

Published: Sep 13th, 2020 3:18 PM

Look back at pharma news in the week to September 11, 2020

"In conjunction of the Gavreto approval in NSCLC, Blueprint also announced that the FDA has accepted pralsetinib new drug application (NDA) in RET- ..."

Published: Sep 11th, 2020 11:11 PM

Pralsetinib receives FDA approval for lung cancer with RET gene fusions

"... cancer types, including NSCLC and medullary thyroid cancer, and treatment options that selectively target these genetic alterations are limited."

Published: Sep 11th, 2020 9:07 PM

FDA Approves Oncomine Dx Target Test Companion Diagnostic for Pralsetinib in RET+ NSCLC

"Specifically, pralsetinib elicited an overall response rate (ORR) of 57% (95% CI, 46%-68%) and a complete response (CR) rate of 5.7% in 87 ..."

Published: Sep 11th, 2020 6:39 PM

GSK and J&J alum Vijay Reddy to take control of R&D at Tmunity; Andrew Hirsch exits Agios for ...

"Tmunity also added to their leadership team by selecting Simona King as their CFO. A nearly 20-year vet of Bristol Myers Squibb in various financial ..."

Published: Sep 11th, 2020 2:51 AM

Health Beat: RETEVMO for thyroid cancer saves man's life

"Ninety percent of all patients are cured if it's caught early, but for those with medullary thyroid cancer, a rare form of the disease, there have been few ..."

Published: Sep 11th, 2020 1:48 AM

FDA Approves Gavreto for Treatment of RET-Positive, Metastatic NSCLC

"The FDA granted accelerated approval to pralsetinib (Gavreto, Blueprint Medicines) for adults with metastatic RET fusionpositive non-small cell lung ..."

Published: Sep 11th, 2020 12:28 AM

Health Beat: RETEVMO for thyroid cancer saves man's life

"Andersen used RETEVMO on Tanner, who was 17. Within a few treatments, Tanner's tumors began to shrink. "My goal was to finish high school and at ..."

Published: Sep 10th, 2020 5:11 PM

Retevmo for thyroid cancer

"RETEVMO was approved in May for people with non-small cell lung cancer, and two types of thyroid cancer with specific gene mutations, including ..."

Published: Sep 10th, 2020 11:12 AM

Gavreto (pralsetinib)

"Medscape - Non-small cell lung cancer dosing for Gavreto (pralsetinib), frequency-based adverse effects, comprehensive interactions, ..."

Published: Sep 10th, 2020 2:33 AM

Lymph node metastasis in hereditary medullary thyroid cancer is independent of the underlying

"Although the onset of hereditary medullary thyroid cancer (MTC) depends on mutational risk, researchers sought to analyze the impact of this risk on ..."

Published: Sep 9th, 2020 9:30 PM

FDA Approvals Roundup: Gavreto and Trulicity

"Gavreto approved for metastatic lung cancer with RET gene fusions ... medullary thyroid cancer and RET fusion-positive thyroid cancer, which are also ..."

Published: Sep 9th, 2020 8:56 PM

FDA Clears Targeted Therapy, Diagnostic for Metastatic RET Fusion-Positive NSCLC

"Pralsetinib (Gavreto), developed by Blueprint Medicines, received accelerated approval. Thermo Fisher Scientific's Oncomine Dx Target Test received ..."

Published: Sep 8th, 2020 7:26 PM

Pralsetinib: Second Drug for RET+ NSCLC Approved in US

"Selpercatinib is also indicated for use in RET+ NSCLC and was approved for use RET+ medullary thyroid cancer and RET+ thyroid cancer."

Published: Sep 8th, 2020 4:40 PM

UPDATED: Roche nabs an FDA OK for Gavreto, triggering a heavyweight bout with rivals at Eli Lilly

"Four months after Eli Lilly's Retevmo got the first FDA OK to treat RET-altered tumors, Roche and Blueprint Medicines are stepping into the ring with ..."

Published: Sep 8th, 2020 11:50 AM

Roche joins competition in new targeted therapy for NSCLC

"The Retevmo trial also showed that 10 out of 11 previously treated NSCLCL patients with brain metastases had intracranial responses (CNS ORR), and ..."

Published: Sep 8th, 2020 4:48 AM

FDA Approves Gavreto for RET Fusion Lung Cancer

"Gavreto (formerly known as BLU-667), developed by Blueprint Medicine in collaboration with Genentech, inhibits a receptor tyrosine kinase known as ..."

Published: Sep 7th, 2020 9:52 PM

II-VI Sell-Off is an Overreaction, Says Five-Star Analyst

"... chemotherapy and for RET mutation-positive medullary thyroid cancer (MTC) that requires systemic treatment and for which there are no acceptable ..."

Published: Sep 7th, 2020 8:45 PM

FDA OKs Blueprint/Roche's Gavreto As Rival To Lilly's Retevmo

"... transfection (RET) fusion-positive non-small cell lung cancer, setting the stage for a head-to-head battle for market share with Eli Lilly's Retevmo."

Published: Sep 7th, 2020 4:15 PM

Blueprint and Roche take on Lilly as FDA approves RET-targeting lung cancer drug

"Approval sets up a rivalry with Eli Lilly's RET inhibitor Retevmo (selpercatinib), and the verdict from experts at this year's American Society of Clinical ..."

Published: Sep 7th, 2020 3:40 PM

Illuminating Hrthle cell carcinoma

"The selective RET kinase inhibitor, selpercatinib (Retevmo; Eli Lilly [NYSE: LLY]), also known as LOXO-292, has been shown to have robust ..."

Published: Sep 7th, 2020 1:48 PM

FDA approves Roche's Gavreto to treat metastatic RET fusion-positive NSCLC

"... (RET) fusion-positive NSCLC, RET-mutant medullary thyroid cancer (MTC), RET fusion-positive thyroid cancer and other RET-altered solid tumours."

Published: Sep 7th, 2020 9:10 AM

Fundraiser for University of Reading law student with cancer to get ONC201 drug

"Fundraiser for University of Reading law student with cancer to get ONC201 drug. By Celine Byford Trainee Reporter. (4). Skip to next photo. 1/4."

Published: Sep 7th, 2020 9:07 AM

Fundraiser for University of Reading law student with cancer to get ONC201 drug

"Fundraiser for University of Reading law student with cancer to get ONC201 drug. By Celine Byford. (3). Skip to next photo. 1/3. Show caption. 1/3."

Published: Sep 5th, 2020 9:18 PM

Exelixis (EXEL) Down 9.4% Since Last Earnings Report: Can It Rebound?

"Cometriq (cabozantinib capsules) for the treatment of medullary thyroid cancer generated $5.1 million in net product revenues. Exelixis earned $16.3 ..."

Published: Sep 5th, 2020 7:37 AM

FDA Grants Priority Review to Pralsetinib for RET+ Thyroid Cancers

"The FDA has granted a priority review to pralsetinib for the treatment of patients with advanced or metastatic RET-mutant medullary thyroid cancer as ..."

Published: Sep 5th, 2020 6:30 AM

Blueprint, Roche take on Lilly with FDA approval for RET cancer drug Gavreto

"It was only May when Eli Lilly's Retevmo became the first FDA-approved drug for RET-altered tumors. Now, a rival therapy has arrived with a better ..."

Published: Sep 5th, 2020 6:07 AM

FDA Approves Pralsetinib in RET Fusion-Positive NonSmall Cell Lung Cancer

"The FDA has approved pralsetinib (formerly BLU-667, Gavreto) for the treatment of adult patients with metastatic RET fusionpositive nonsmall cell ..."

Published: Sep 5th, 2020 3:52 AM

Genentech Announces FDA Approval of Gavreto (pralsetinib) for the Treatment of Adults With ...

"RET-activating fusions and mutations are key disease drivers in many cancer types, including NSCLC and medullary thyroid cancer (MTC), and ..."

Published: Sep 2nd, 2020 11:56 PM

Selpercatinib Demonstrates Durable Efficacy and Intracranial Activity in RET+ NSCLC

"The RET inhibitor selpercatinib (LOXO-292; Retevmo) was shown to have durable efficacy with mostly low-grade adverse effects (AEs) in patients with ..."

Published: Sep 2nd, 2020 11:33 PM

Expert Highlights Major Advancements in Honor of Thyroid Cancer Awareness Month

"In addition, another RET inhibitor, pralsetinib (BLU-667), is also appearing promising for the treatment of RET-mutant MTC and papillary thyroid cancer ( ..."

Published: Sep 2nd, 2020 9:07 PM

RET Inhibitor Demonstrates Efficacy in RET-Altered Thyroid Cancer

"RET alterations are present among 70% of patients with in medullary thyroid cancers (MTC) and 10% of other thyroid cancers, but RET-specific ..."

Published: Sep 2nd, 2020 6:52 PM

BMS oncology chief Namouni lands at Blueprint Medicines to lead R&D

"Fouad Namouni, M.D., arrives after Roche forked over $775 million in cash and equity for the rights to pralsetinib outside the U.S. and China."

Published: Sep 2nd, 2020 4:25 PM

Another Big Pharma 'lifer' in the top ranks of R&D is starting a new chapter in biotech

"Namouni will likely be coming on board just one step ahead of an approval for pralsetinib, Blueprint's RET rival to Eli Lilly's Retevmo, which got out in ..."

Published: Aug 29th, 2020 11:00 PM

New Lung, Thyroid Cancer Tx; COVID Risk in Cancer: It's TTHealthWatch!

"In the thyroid cancers, they had 55 patients with the medullary thyroid cancer previously treated. Sixty-nine percent had a response to the agent with 82 ..."

Published: Aug 28th, 2020 10:37 PM

Adults With Rare Blood Cancers Can Now Receive Treatment From Home

"... as mutation or fusion, in the RET gene, and it is able to treat non-small cell lung cancer, medullary thyroid cancer, and other types of thyroid cancers."

Published: Aug 28th, 2020 8:56 PM

LIBRETTO-001 Trial Shows Promise for Selpercatinib in NSCLC Marked by RET Gene Fusions

"Results from this trial observed in patients with RET-altered lung and thyroid cancers also led to the approval of selpercatinib by the FDA in May for ..."

Published: Aug 28th, 2020 7:48 PM

Trending News on Targeted Oncology, Week of August 28, 2020

"Selpercatinib demonstrated durable efficacy as treatment of patients with medullary thyroid cancer harboring the RET mutation whether or not they ..."

Published: Aug 27th, 2020 7:26 PM

Selpercatinib may provide an effective response against RET-mutated thyroid cancer

"Selpercatinib, a highly selective RET kinase inhibitor, was effective in antitumor activity against medullary thyroid cancer. 2. Selpercatinib caused ..."

Published: Aug 27th, 2020 5:56 PM

Selpercatinib Induced Durable Efficacy in RET Fusion-Positive NSCLC

"... which evaluated selpercatinib (formerly known as LOXO-292; Retevmo) as treatment of patients with RET fusion-positive nonsmall cell lung cancer ..."

Published: Aug 27th, 2020 2:59 PM

Selpercatinib Shows Durable Efficacy in RET Fusionpositive NSCLC

"Selpercatinib is a novel, ATP-competitive, highly selective small-molecule inhibitor of RET kinase. Selpercatinib was designed to penetrate the central ..."

Published: Aug 27th, 2020 2:11 AM

Selpercatinib May Be New Standard of Care for RET-Altered Thyroid Cancers, Study Shows

"Researchers suggest that the void could potentially be filled with selpercatinib (formerly known as LOXO-292; Retevmo). Selpercatinib is the first ..."

Published: Aug 27th, 2020 2:00 AM

New Targeted Lung Cancer Drug, Retevmo, So Effective It Gave Musician His Life Back

"RET+ lung cancers are aggressive and have a poor prognosis, but new targeted drug selpercatinib (Retevmo) benefits more than 90% of patients who ..."

Published: Aug 27th, 2020 1:48 AM

Efficacy of Selpercatinib in RET FusionPositive NonSmall-Cell Lung Cancer

"Selpercatinib had durable efficacy, including intracranial activity, with mainly low-grade toxic effects in patients with RET fusionpositive NSCLC who ..."

Published: Aug 24th, 2020 5:01 PM

Tri-Cities hockey league, gamers join forces for 5th-grader fighting rare cancer

"When he came in for imaging tests, they discovered medullary thyroid cancer. That form of cancer accounts for just 1 to 2 percent of the already ..."

Published: Aug 20th, 2020 2:00 AM

Selpercatinib Aimed at RET-Altered Cancers

"Selpercatinib Aimed at RET-Altered Cancers. List of authors. Razelle Kurzrock, M.D.. August 27, 2020. N Engl J Med 2020; 383:868-869"

Published: Aug 18th, 2020 7:26 PM

Vandetanib confers clinical benefit for certain patients with medullary thyroid cancer

""Medullary thyroid cancer is a rare neuroendocrine malignancy that derives from parafollicular cells of the thyroid gland that secrete the polypeptide ..."

Published: Aug 15th, 2020 12:41 AM

What Are the Warning Signs of Thyroid Cancer?

"Medullary thyroid cancer: Medullary thyroid cancer arises in the C cells in the thyroid gland. C cells produce a hormone called calcitonin. Elevated levels ..."

Published: Aug 11th, 2020 11:50 AM

Thyroid cancer cells signs and symptoms: What are the signs of thyroid cancer?

"Medullary thyroid carcinoma cn run in fmilies, nd npestic thyroid crcinom is extremely rre nd normlly found in people over 60."

Published: Aug 7th, 2020 8:13 PM

Exelixis' (EXEL) Q2 Earnings and Revenues Surpass Estimates

"Cometriq (cabozantinib capsules) for the treatment of medullary thyroid cancer generated $5.1 million in net product revenues. Exelixis earned $16.3 ..."

Published: Aug 6th, 2020 8:20 PM

Neuroendocrine Tumors Market 2020-2026 Emerging Trends | Major Giants Ipsen Pharma ...

"Carcinoid tumors in the lungs; Pancreatic neuroendocrine tumors; Medullary thyroid carcinoma; Merkel cell carcinoma; Pheochromocytoma of the ..."

Published: Aug 3rd, 2020 5:00 PM

A 67-Year-Old Woman With Differentiated Thyroid Cancer

"Those 2 diagnoses are anaplastic, or undifferentiated thyroid cancer. Then the other diagnosis is medullary thyroid cancer. Transcript edited for clarity."

Published: Jul 31st, 2020 8:22 PM

Blueprint Medicines' (BPMC) Q2 Earnings Miss, Revenues Beat

"Blueprint Medicines and Roche will co-develop pralsetinib globally in RET-altered solid tumors, including non-small cell lung cancer (NSCLC), ..."

Published: Jul 31st, 2020 12:41 AM

Medullary Thyroid Carcinoma in a Patient with MEN 1 Syndrome. Case Report and Literature Review

"Abstract: Medullary thyroid cancer (MTC) is typically associated with multiple endocrine neoplasia type 2 syndrome (MEN 2), but not with multiple ..."

Published: Jul 29th, 2020 1:37 AM

Phosphoprotein biomarkers to guide cancer therapy are identified

"To find biomarkers, the researchers first used a unique mouse model of medullary thyroid carcinoma, or MTC, whose growth of the tumor can be ..."

Published: Jul 28th, 2020 11:56 PM

License to Pill: Biotech and pharma deals from July 11-July 24

"... for treating RET-altered non-small cell lung cancer, medullary thyroid cancer and other types of thyroid cancer, as well as other solid tumors."

Published: Jul 28th, 2020 2:45 PM

Aviation Active Noise and Vibration Control System Market Trend Shows A Rapid Growth By 2026 ...

"Medullary Thyroid Cancer Treatment Market 2020 Global Future Growth| Size, Share, Demand, Regional Trends, Segmentation and Forecasts to ..."

Published: Jul 25th, 2020 1:15 PM

Dil Bechara: What Ailed Kizzie Basu? Here's All You Need To Know About Thyroid Cancer

"Types of Thyroid cancer include Papillary thyroid cancer, Follicular thyroid cancer, Anaplastic thyroid cancer, and Medullary thyroid cancer. These types ..."

Published: Jul 24th, 2020 12:07 AM

SEngine Organoid Testing Leads to Treatment Change for Two Metastatic Colorectal Cancer ...

"... to the multi-tyrosine kinase inhibitor vandetanib (Sanofi/Genzyme's Caprelsa), currently approved for medullary thyroid cancer, but noted no disease ..."

Published: Jul 23rd, 2020 6:52 PM

Lilly's Patient Centric Approach Speeds Treatments To Patients

"Retevmo entered clinical testing in May of 2017 and received FDA approval less than three years later. Jacob Van Naarden, COO for Loxo Oncology at ..."

Published: Jul 22nd, 2020 1:03 PM

Pulmonary function in patients with multiple endocrine neoplasia 2B

"... characterize pulmonary function among patients encountering multiple endocrine neoplasia type 2B (MEN2B). Experts analyzed pulmonary function ..."

Published: Jul 22nd, 2020 3:52 AM

Industry News: Roche collaborates with Blueprint Medicines to bring a new treatment to people ...

"... RET-altered non-small cell lung cancer (NSCLC), medullary thyroid cancer (MTC) and other types of thyroid cancer, as well as other solid tumors."

Published: Jul 22nd, 2020 1:37 AM

The Oncologist's Role With Savvy Patients

"It's long been associated with thyroid cancer, particularly medullary thyroid cancer, but now it's been found through deeper and deeper genomics in a ..."

Published: Jul 21st, 2020 1:14 AM

FDA Approval Insights: Selpercatinib in RET+ NSCLC and Thyroid Cancers

"... treatment of patients with RET alterationpositive nonsmall cell lung cancer (NSCLC), medullary thyroid cancer (MTC), and other thyroid cancers."

Published: Jul 20th, 2020 11:33 PM

Cabozantinib Market Emerging Trends, Strong Application Scope, Size, Status, Analysis and ...

"Medullary Thyroid Cancer Treatment; Second Line Treatment for Renal Cell Carcinoma. Details specified in the document: Consumption graphs of all ..."

Published: Jul 19th, 2020 5:45 PM

Look back at pharma news in the week to July 17, 2020

"Roche was also in the news for its collaboration with Blueprint Medicines on the development of the US biotech's targeted cancer candidate pralsetinib."

Published: Jul 17th, 2020 9:52 PM

Trending News on Targeted Oncology, Week of July 17, 2020

"... in progression-free survival in patients with symptomatic and progressive medullary thyroid cancer in a post-hoc analysis of the phase III ZETA trial."

Published: Jul 17th, 2020 2:33 AM

Targeted oncogene therapy before surgery in pediatric patients with advanced invasive thyroid ...

"Mostly pediatric patients with thyroid cancer initially present with operable disease, however, there are some ... the response to therapy and long-term tolerance in patients with widely invasive medullary thyroid cancer, in whom the ..."

Published: Jul 16th, 2020 1:15 PM

Father Admits 'Helping' With Son's Prizewinning Cancer Project

"A high schooler from the southwestern municipality of Chongqing won first prize in the 34th CASTIC for her research on medullary thyroid cancer, ..."

Published: Jul 15th, 2020 5:45 PM

Blueprint Medicines Corporation Collaborates Roche as (BPMC) soars 3.60% in a week

"Pralsetinib is an investigational once-daily oral precision therapy that is used to treat cancer patients driven by oncogenic RET alterations. Under the ..."

Published: Jul 15th, 2020 4:37 PM

Roche pays $775m upfront to access Blueprint's RET programme

"... fusion-positive non-small cell lung cancer (NSCLC), RET mutation-positive medullary thyroid cancer (MTC) and RET fusion-positive thyroid cancer."

Published: Jul 15th, 2020 4:15 PM

Roche-Blueprint ink licensing and collaboration deal for pralsetinib

"Pralsetinib is a once-daily, investigational oral precision therapy offered by Blueprint, which has been used for the treatment of patients with RET-altered ..."

Published: Jul 15th, 2020 11:56 AM

AZN, IQV Team Up To Accelerate COVID-19 Vaccine Work, RIGL's ITP Drug Repurposed, IMV On ...

"In addition, a safety trial in dry eye disease patients is expected to be ... cancer, medullary thyroid cancer, other thyroid cancers, and other solid tumors."

Published: Jul 15th, 2020 2:33 AM

Roche Invests in Blueprint Medicines, Maker of RET Inhibitor Pralsetinib

"... medullary thyroid cancer (MTC) and RET fusionpositive thyroid cancers. ... "Beyond lung cancer, pralsetinib's tumour-agnostic potential further ..."

Published: Jul 15th, 2020 12:52 AM

Roche to Pay $775M to Blueprint Medicines for Rights to Pralsetinib for RET-Altered Tumors

"... cell lung cancer, medullary thyroid cancer, as well as other solid tumors. ... for pralsetinib in RET-mutant and RET fusion-positive thyroid cancers."

Published: Jul 15th, 2020 12:48 AM

Noteworthy Tuesday Option Activity: INTU, CTXS, HON

"Pralsetinib, proposed for the treatment of RET fusion-positive NSCLC, RET mutation-positive MTC, and RET fusion-positive thyroid cancer, is under FDA ..."

Published: Jul 14th, 2020 9:18 PM

Should Value Investors Buy Asbury Automotive Group (ABG) Stock?

"Separately, 60% of previously treated and 74% of treatment naive RET-mutant medullary thyroid cancer patients responded to pralsetinib. Roche's ..."

Published: Jul 14th, 2020 8:26 PM

Elmont continues to face high cancer rates

"In one case, Mimi Pierre-Johnson said, a man who had lived in Elmont for more than 40 years was diagnosed with medullary thyroid cancer, despite ..."

Published: Jul 14th, 2020 8:00 PM

Roche pits its targeted cancer Blueprint against Lilly

"Lilly's own Ret inhibitor Retevmo (selpercatinib) was recently approved in Ret-mutated non-small cell lung and thyroid cancers, giving it a few months' ..."

Published: Jul 14th, 2020 7:01 PM

Could A $775 Million Roche-Blueprint Deal Unseat Eli Lilly In Cancer?

"Retevmo was the first cancer treatment to target RET and gain FDA approval. Blueprint and Roche hope to follow. The biotech company has already ..."

Published: Jul 14th, 2020 5:06 PM

Roche collaborates with Blueprint Medicines for new treatment of RET-altered cancers

"Blueprint Medicines has submitted a new drug application (NDA) for pralsetinib to the US Food and Drug Administration (FDA) and a marketing ..."

Published: Jul 14th, 2020 3:52 PM

Roche to pay Blueprint $775M for pralsetinib rights, setting up showdown with Lilly

"Lilly won FDA approval for Retevmo in the treatment of NSCLC and two types of thyroid cancer in May. Blueprint is targeting the same indications and ..."

Published: Jul 14th, 2020 3:09 PM

Diagnostic champ Roche buys its way into the RET title fight with Eli Lilly, paying $775M in cash to ...

"Four years later, pralsetinib is on the cusp of potential approval and the Swiss pharma giant is putting in much more to get in on the commercial game."

Published: Jul 14th, 2020 12:52 PM

Roche gene testing key to $1.7 billion deal for Blueprint cancer drug

"The Swiss drugmaker will pay $675 million in cash and make a $100 million equity investment in Blueprint for rights to pralsetinib, which could gain ..."

Published: Jul 14th, 2020 11:50 AM

Vienna Airport June passenger numbers down 95%

"Earlier this month, Blueprint also submitted pralsetinib to the FDA for treating advanced RET mutant and RET fusion-positive thyroid cancers. "In bringing ..."

Published: Jul 12th, 2020 5:00 PM

Vandetanib Remains Safe and Effective in Medullary Thyroid Cancer

"A post-hoc analysis of the phase III ZETA trial shows that vandetanib improved PFS in medullary thyroid cancer. The tyrosine kinase inhibitor vandetanib ..."

Published: Jul 10th, 2020 9:52 PM

Coronavirus: Kiwi diagnosed with rare cancer in Romania struggling to get home

"It revealed he had stage four medullary thyroid cancer. Nick Daniels has stage four thyroid cancer. He is trying to come home to Auckland. Nick Daniels/ ..."

Published: Jul 6th, 2020 11:20 AM

Parents of boy, 4, with rare cancer pin hopes on experimental drug

"... ONC201 trials had "shown minimal to no efficacy". However, "if the mother needs to feel that she has done everything, we will help her in her efforts."

Published: Jul 3rd, 2020 12:29 AM

NCI Trials for July 2020

"NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Phase 2 Subprotocol of LOXO-292 in Patients with Tumors Harboring RET ..."

Published: Jul 2nd, 2020 5:56 PM

FDA Approval Sought for Pralsetinib to Treat Advanced RET+ Thyroid Cancers

"... treatment of patients with advanced or metastatic RET-mutant medullary thyroid cancer (MTC) and RET fusionpositive thyroid cancers, according to ..."

Published: Jul 2nd, 2020 10:22 AM

LMNL Joins COVID-19 Battle, PFE/BNTX Vaccine Data Promising, EVLO On Watch

"Pralsetinib is an investigational, once-daily precision therapy designed to potently and selectively inhibit RET fusions and mutations, including ..."

Published: Jul 2nd, 2020 3:17 AM

FDA Approval Sought for Pralsetinib in RET+ Medullary Thyroid Cancer

""Pralsetinib has broad potential to address the medical needs of patients with RET-altered cancers, who have not traditionally benefited from targeted ..."

Published: Jul 2nd, 2020 12:41 AM

Blueprint Medicines Files NDA for Pralsetinib for RET-Driven Thyroid Cancers

"The FDA granted accelerated approval to selpercatinib in May for patients with RET fusion-positive NSCLC, RET-mutant medullary thyroid cancer, and ..."

Published: Jul 1st, 2020 6:18 PM

Estrogen Receptor Agent Approved

"Retevmo Approved in Lung and Thyroid Cancers. On May 8, the U.S. Food and Drug Administration (FDA) announced the approval of Retevmo ( ..."

Published: Jul 1st, 2020 2:56 AM

Progress in Targeted Therapy for Lung Cancer: New Data From ASCO 2020

"Please note that in the selpercatinib approval, it is available for any line of therapy and should be considered as a first therapy. Looking for RET is ..."

Published: Jun 29th, 2020 6:41 PM

Burning Rock Bio, CStone Pharmaceuticals to Codevelop CDx for Pralsetinib in China

"Pralsetinib is an investigational treatment for the detection of RET alterations in cancer patients. Burning Rock Chief Medical Officer Hao Liu said in a ..."

Published: Jun 29th, 2020 6:09 AM

BRIEF-Burning Rock And CStone Pharmaceuticals Reached Strategic Collaboration On Co ...

"... Rock And CStone Pharmaceuticals Reached Strategic Collaboration On Co-Development Of Companion Diagnostics For Pralsetinib In China."

Published: Jun 26th, 2020 7:07 PM

Pulmonary abnormalities, lung cysts seen in children, young adults with MEN2B

""This study evaluated lung function and anatomy in patients with MEN2B using pulmonary function tests and available CT images," Jaydira Del Rivero, ..."

Published: Jun 24th, 2020 10:15 AM

Dr. Halmos on Recent Advancements in NonSmall Cell Lung Cancer

"Another advance is the development and the awaited approval of pralsetinib (BLU-667). These agents are exceptional treatment options for patients ..."

Published: Jun 22nd, 2020 6:05 PM

NCCN Updates Clinical Practice Guideline for Thyroid Carcinomas

"After FNA results yield a medullary thyroid carcinoma diagnosis, a new bullet is listed under diagnostic procedures for additional cross-sectional ..."

Published: Jun 20th, 2020 12:52 AM

VIDEO: Advantages of aggressive therapy for metastatic EGFR-mutated NSCLC

"Rotow also mentioned the recent FDA approval of selpercatinib for the treatment of RET fusion-positive NSCLC. She highlighted findings from a ..."

Published: Jun 19th, 2020 11:45 PM

Non-small-cell lung cancer therapies lead FDA approvals in May

"In addition to Tabrecta and Retevmo were Qinlock (ripretinib, Deciphera Pharmaceuticals Inc.), a kinase inhibitor, for advanced gastrointestinal ..."

Published: Jun 18th, 2020 6:30 PM

$400000 SBIR grant fast-tracks new approach to treating lung, thyroid cancers

"KinaRx portfolio includes therapeutic candidates for acute myeloid leukemia, lung cancer, and medullary thyroid cancer, among others. About Purdue ..."

Published: Jun 15th, 2020 8:56 PM

Selpercatinib shows durable response in RET-fusion positive NSCLC

""LOXO-292, or selpercatinib, is a highly potent selective RET-inhibitor," Vivek Subbiah, MD, associate professor at The University of Texas MD Anderson ..."

Published: Jun 15th, 2020 5:00 PM

Increasing incidence of cancer and stage migration towards advanced disease in children and ...

"... whereas stage migration towards advanced disease was seen for Hodgkin lymphomas, soft tissue sarcomas and medullary thyroid carcinomas."

Published: Jun 12th, 2020 5:55 PM

Nurses Unlock Role in Cancer Genetics

"People found to have a genetic mutation for medullary thyroid cancer can encourage family members to undergo screening, as there is a nearly 100% ..."

Published: Jun 11th, 2020 7:03 PM

Pralsetinib Appears Promising in RET Fusion-Positive NSCLC

"Pralsetinib, an oral selective RETkinase inhibitor, targets both RET fusions and alterations. For the ARROW study (ClinicalTrials.gov identifier: ..."

Published: Jun 11th, 2020 3:18 AM

Genetic Testing Becomes Vital in Sequencing Treatments for Patients With Thyroid Cancer

"The highly selective RET inhibitor pralsetinib (BLU-667), for example, is under investigation now and has shown encouraging findings in thyroid ..."

Published: Jun 9th, 2020 9:18 PM

NeoGenomics, Lilly Oncology Partner for Thyroid Cancer Testing Program

"... for metastatic medullary thyroid cancer patients, or the NGS Thyroid Profile plus RET FISH test for non-metastatic medullary thyroid cancer patients."

Published: Jun 8th, 2020 11:56 PM

Real Housewife Alum Jill Zarin on Finding Love After Cancer Loss: Says Husband Would Approve ...

"Medullary thyroid cancer accounts for approximately 2% of all thyroid cancers. Approximately 25% of all medullary thyroid cancer is inherited, and a test ..."

Published: Jun 7th, 2020 6:07 PM

Fundraising vital as family of Eva Williams wait to see if she will be accepted on to one of four ...

"... all essentially means is that the trials aren't readily accessible and we feel as though time is probably running out on us accessing the ONC201 trial."

Published: Jun 7th, 2020 1:48 PM

Selpercatinib Prompts Dramatic Response in RET Fusion-Positive Ansplastic Thyroid Carcinoma

"... RET-mutant medullary thyroid cancer and those with other RET fusion-positive thyroid cancers in the phase I/II LIBRETTO-001 trial (NCT03157128), ..."

Published: Jun 6th, 2020 4:03 AM

"Mommy, my brain hurts," a kindergartner tells her mother. The girl is then diagnosed with a brain ...

"ONC201, an experimental drug, is part of a Phase I testing study at the hospital, Raegen Sieck said. "We are going to put all of our hope and faith into ..."

Published: Jun 5th, 2020 8:22 PM

Blueprint Medicines (BPMC) Up 15.5% Since Last Earnings Report: Can It Continue?

"Additionally, pralsetinib is being studied for the treatment of RET-mutant medullary thyroid carcinoma (MTC). The company is further on track to file an ..."

Published: Jun 5th, 2020 6:18 PM

RET Inhibition Shows Significant Intracranial Responses in RET-Altered NSCLC

""Selpercatinib had marked intracranial anti-tumor activity in RET fusionpositive patients with [NSCLC and] CNS metastases. Tumor responses were ..."

Published: Jun 4th, 2020 9:18 AM

Exelixis (EXEL) Down 11.5% Since Last Earnings Report: Can It Rebound?

"... of medullary thyroid cancer generated $4.7 million in net product revenues. ... Tecentriq in patients with locally advanced or metastatic solid tumors."

Published: Jun 3rd, 2020 8:00 PM

Asco 2020 movers cell therapy companies dominate the risers

"Supportive sellside analysts duly described TPX-0046 as potentially best-in-class, no doubt mindful of the $325m offering that Turning Point had ..."

Published: Jun 3rd, 2020 8:56 AM

$2 million SBIR grant fast-tracks cancer drug platform technology

"KinaRx portfolio includes therapeutic candidates for acute myeloid leukemia, lung cancer, medullary thyroid cancer, among others. About Purdue ..."

Published: Jun 2nd, 2020 11:56 PM

Blueprint's Positive Pralsetinib Data Places New Option on Horizon for RET-Altered Cancer Patients

"... medullary thyroid cancer, and RET fusion-positive thyroid cancer. ... In this 27-patient cohort, 13 patients had RET fusion-positive thyroid cancer, and ..."

Published: Jun 2nd, 2020 7:38 PM

US FDA approval tracker: several early decisions in May

"Retevmo, which Lilly gained through its Loxo acquisition, was approved in ... Retevmo (selpercatinib), Eli Lilly, 1,172, Approved (early ~2 months)."

Published: Jun 2nd, 2020 2:22 AM

A Look Back at the FDA News from May 2020

"Pralsetinib (BLU-667) was granted a priority review on May 29, 2020, for the treatment of patients with advanced solid tumors harboring RET ..."

Published: Jun 1st, 2020 8:00 PM

Pralsetinib Active Across RET+ Tumor Types and Gains FDA Review

"RET inhibitor pralsetinib (BLU-667) induced responses in a number of patients with rare and difficult to treat RET fusionpositive solid tumors."

Published: Jun 1st, 2020 5:56 PM

Turning Point Therapeutics to Participate in Goldman Sachs 41st Annual Global Healthcare ...

"... TPX-0046, targeting RET and SRC, which is being studied in a Phase 1/2 trial of patients with advanced or metastatic solid tumors harboring genetic ..."

Published: Jun 1st, 2020 5:45 AM

Pralsetinib Demonstrates Significant Findings in RET+ Solid Tumors as FDA Grants Priority Review

"In thyroid cancers specifically, RET fusions can be found in about 10% to 20% of papillary thyroid cancers (PTCs), mutations are found in about 50% of ..."

Published: May 31st, 2020 8:00 PM

Blueprint gets FDA priority review for competitor to newly approved Lilly cancer drug

"... medullary thyroid cancer. Blueprint said it plans to file for FDA approval of pralsetinib in RET mutant- and fusion-positive thyroid cancers next month."

Published: May 31st, 2020 10:15 AM

Jefferson, Chad

"... son of Charles and Connie Jefferson, passed away from complications of a brain injury during his battle with Medullary Thyroid Cancer, while being ..."

Published: May 31st, 2020 5:18 AM

ASCO 2020: Targeted therapy pralsetinib achieves high response rates in advanced cancers with ...

"The targeted therapy pralsetinib appears to have high response rates and durable activity in patients with a broad variety of tumours harbouring RET ..."

Published: May 31st, 2020 2:45 AM

ASCO 2020: Oncoceutics' ONC201 Demonstrates Clinical Benefit

"To date, tumors with an H3 K27M mutation have no effective treatments. They are also associated with poor overall survival. ONC201, a "founding ..."

Published: May 30th, 2020 3:51 AM

Other news to note for May 29, 2020

"TPX-0046 also demonstrated antitumor activity in RET-driven cell-derived and patient-derived xenograft tumor models, including those that harbor a ..."

Published: May 29th, 2020 7:15 PM

Targeted therapy pralsetinib achieves high response rates in advanced cancers with RET gene ...

"RET alterations are most common in medullary thyroid cancers (approximately 90% of advanced cases), papillary thyroid cancers (approximately ..."

Published: May 29th, 2020 5:33 PM

BRIEF-Turning Point Therapeutics Presents Preclinical Data For Novel RET Inhibitor Candidate

"TURNING POINT THERAPEUTICS INC - A PHASE 1/2 TRIAL OF TPX-0046 IN RET TKI-NAVE AND -PRETREATED PATIENTS IS ONGOING Source ..."

Published: May 29th, 2020 5:00 PM

BRIEF-Blueprint Medicines Highlights Durable Clinical Activity And Well-Tolerated Safety Profile Of ...

"* BLUEPRINT MEDICINES CORP - NDA ACCEPTED BY FDA AND MAA VALIDATED BY EMA FOR PRALSETINIB IN RET FUSION-POSITIVE NSCLC ..."

Published: May 28th, 2020 2:37 AM

Pulmonary function in patients with multiple endocrine neoplasia 2B (MEN2B)

"They included 36 patients with MEN2B (18 males, 18 females) based on the availability of PFTs; 27 patients had undergone at least two PFTs and ..."

Published: May 27th, 2020 5:56 PM

Pulmonary and thyroid carcinoma: FDA approves the treatment with Retevmo

"The Food and Drug Administration (FDA) approved Retevmo (selpercatinib) for three types of cancer treatment that present alteration (changing) in the ..."

Published: May 20th, 2020 2:00 AM

8 recent drug approvals

"The FDA approved Retevmo, Eli Lilly's drug designed to treat three types of tumors non-small cell lung cancer, medullary thyroid cancer and other ..."

Published: May 19th, 2020 7:37 PM

Multiple Treatment Guideline Updates Released for Lung Cancer

"Selpercatinib was added as a "preferred" first-line and subsequent treatment option (category 2A), cabozantinib and vandetanib were added as ..."

Published: May 19th, 2020 5:45 AM

Turning Point Therapeutics Announces Pricing of $325 Million Public Offering of Common Stock

"... trial of patients with advanced or metastatic solid tumors harboring genetic alterations in MET; TPX-0046, targeting RET and SRC, which is currently ..."

Published: May 16th, 2020 12:52 AM

Onc Daily: Olaparib in Ovarian Cancer, Smoking and Lung Cancer Survival

"Update on Medullary Thyroid Carcinoma. The Medscape reference team has updated the detailed information on medullary thyroid carcinoma to include ..."

Published: May 15th, 2020 8:33 PM

Blueprint's Ayvakit gets FDA no-go in new stomach cancer use but presses ahead in blood disorder

"In a phase 2 trial, pralsetinib triggered a response in 65% of patients with RET fusion-positive NSCLC, according to updated data set for presentation ..."

Published: May 15th, 2020 7:03 PM

Selpercatinib receives FDA nod

"The presence of RET alterations must be confirmed via laboratory testing before initiating treatment with selpercatinib. Advertisement. The approval is ..."

Published: May 15th, 2020 2:45 AM

Retevmo Approved for RET-Driven NSCLC and Thyroid Cancers

"adults and children at least 12 years of age with advanced or metastatic RET-mutant medullary thyroid cancer (MTC) who require systemic therapy; ..."

Published: May 15th, 2020 1:37 AM

With new lung cancer data at ASCO, Blueprint Medicines nips at Eli Lilly's heels

"The company will present a poster on pralsetinib, its RET inhibitor, which some analysts wrote they view as being "interchangeable" with Lilly's Retevmo, ..."

Published: May 14th, 2020 6:41 PM

FDA approves Retevmo, first therapy for lung and thyroid cancers with RET gene alterations

"FDA has approved Retevmo (selpercatinib) capsules to treat non-small cell lung cancer, medullary thyroid cancer and other types of thyroid cancers in ..."

Published: May 14th, 2020 5:56 PM

Blueprint Medicines Announces Data Presentations Highlighting Significant Progress in Advancing ...

"Oral Presentation. Presentation Title: Clinical activity of the RET inhibitor pralsetinib (BLU-667) in patients with RET fusion+ solid tumors. Session Title: ..."

Published: May 14th, 2020 3:07 PM

FDA Approves RET Inhibitor Retevmo for Lung and Thyroid Cancer

"Medullary thyroid cancer, which involves a specific type of cell, is uncommon-accounting for only 4% of all thyroid cancers-but it frequently has RET ..."

Published: May 14th, 2020 3:07 AM

Biotech ETFs to Gain From Latest Advancements in Cancer Drugs

"... cell lung cancer, medullary thyroid cancer and other types of thyroid cancers in patients whose tumors have an alteration (mutation or fusion) in a ..."

Published: May 14th, 2020 2:33 AM

Lilly Cancer Treatment Lands FDA Approval

"... cancer, as well as the treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic RET-mutant medullary thyroid ..."

Published: May 14th, 2020 2:05 AM

Days after rapid FDA approval, Lilly and Blueprint go head-to-head again at ASCO

"Lilly got an edge with an FDA approval for its drug, called selpercatinib or Retevmo, last week - months ahead of the agency deadline - but ..."

Published: May 14th, 2020 2:03 AM

ASCO: Blueprint's RET inhibitor pads its case ahead of FDA lung cancer decision

"Pralsetinib, also called BLU-667, shrank tumors in 100% of those patients. Nearly three-quarters of them had enough shrinkage to be responders."

Published: May 14th, 2020 2:00 AM

ASCO: Blueprint's RET inhibitor pads its case ahead of FDA lung cancer decision

"Blueprint submitted pralsetinib for FDA approval as a treatment for RET fusion-positive NSCLC in the first quarter this year, and with a priority review ..."

Published: May 13th, 2020 11:11 PM

The Role of Multikinase TKIs for NSCLC

"Shirish M. Gadgeel, MD, MBBS: The efficacy results with multikinase tyrosine kinase inhibitors are better in patients with medullary thyroid carcinoma ..."

Published: May 12th, 2020 3:07 PM

Lilly's Retevmo wins US nod for specific lung, thyroid cancers

"US regulators have approved Eli Lilly's Retevmo (selpercatinib) as the first therapeutic specifically designed for patients with advanced RET-driven ..."

Published: May 12th, 2020 3:11 AM

Retevmo (selpercatinib) FDA Approval History

"Retevmo (selpercatinib) is a kinase inhibitor for the treatment of patients with advanced RET fusion-positive non-small cell lung cancer (NSCLC), ..."

Published: May 12th, 2020 1:15 AM

Under Armour, Marriott fall; Cardinal Health, AMC rise

"The pharmaceutical company's cancer drug Retevmo was approved by the Food and Drug Administration. Quidel Corp., up $50.35 to $208.95."

Published: May 12th, 2020 12:18 AM

Blueprint Medicines up 11% on prospects of RET inhibitor pralsetinib

"Blueprint Medicines (BPMC +10.7%) is poised for its best one-day gain in a month on the heels of a note from SVB Leerink on RET inhibitor pralsetinib ..."

Published: May 11th, 2020 11:56 PM

Onc Daily: Selpercatinib Approved, ASCO Goes Virtual

"... of RET-positive tumors in adults with nonsmall cell lung cancer that has spread; the treatment of advanced medullary thyroid cancer (MTC) or MTC ..."

Published: May 11th, 2020 9:41 PM

Recon: FDA approves Lilly's Retevmo for thyroid, lung cancers; China approves Novartis' MS drug ...

"Recon: FDA approves Lilly's Retevmo for thyroid, lung cancers; China approves Novartis' MS drug Mayzent. Posted 11 May 2020 | By Michael Mezher."

Published: May 11th, 2020 8:56 PM

FDA Approves Selpercatinib for Certain NonSmall Cell Lung, Thyroid Cancers

"Selpercatinib is a kinase inhibitor which helps to prevent cancer cells from growing. Prior to beginning treatment, an RET gene mutation must be ..."

Published: May 11th, 2020 8:33 PM

Opdivo-Yervoy Combination Continues to Show Superior Long-Term Outcomes in Renal Cell ...

""The ORRs in patients with intermediate- and poor-risk disease who received ... NSCLC that has spread in adults; Advanced medullary thyroid cancer ..."

Published: May 11th, 2020 8:22 PM

Lilly cashes in on Loxo buyout with FDA approval for first-in-class cancer drug Retevmo

"Blueprint's RET inhibitor pralsetinib, also known as BLU-667, hit a 61% response rate in RET fusion-positive NSCLC patients. The company recently ..."

Published: May 11th, 2020 5:11 PM

FDA approves Retevmo for lung cancer, thyroid cancer subsets

"... RET fusion-positive non-small cell lung cancer that has spread; advanced RET fusion-positive medullary thyroid cancer or medullary thyroid cancer ..."

Published: May 11th, 2020 4:06 PM

Drugmakers Overhaul the Sales Pitch Amid Coronavirus Lockdowns

"The new Lilly drug, Retevmo, treats lung and thyroid cancers that have certain genetic traits. After many employees began working from home in ..."

Published: May 11th, 2020 2:56 PM

FDA clears Lilly's Retevmo for RET-positive lung, thyroid cancers

"Retevmo reaches the market after Loxo's Vitrakvi (larotrectinib), which was approved by the FDA to treat any solid tumour that has a neurotrophic ..."

Published: May 10th, 2020 10:00 PM

UPDATED: A groundbreaking cancer drug nabs fast OK, giving Eli Lilly boasting rights as a rival ...

"Regulators stamped their OK on selpercatinib, which can now be marketed as Retevmo to patients suffering from 3 different types of cancers all driven ..."

Published: May 10th, 2020 9:52 PM

A groundbreaking cancer drug nabs fast OK, giving Eli Lilly boasting rights as a rival speeds close ...

"The FDA action covers RET fusion-positive non-small cell lung cancer and thyroid cancer, along with RET-mutant medullary thyroid cancer."

Published: May 10th, 2020 4:37 PM

Lilly Receives US FDA Approval for Retevmo (selpercatinib), the First Therapy Specifically for ...

""The approval of selpercatinib marks an important milestone in the treatment of NSCLC, making RET-driven cancers now specifically targetable in the ..."

Published: May 10th, 2020 12:19 AM

Lilly's Loxo buyout bears fruit as FDA clears cancer drug Retevmo

"Retevmo is the eighth cancer drug approved by the FDA this year, following new medicines for breast, lung, liver and gastrointestinal cancers. Later this ..."

Published: May 9th, 2020 12:30 PM

Retevmo (selpercatinib) FDA Approval History

"FDA approval history for Retevmo (selpercatinib) used to treat Non-Small Cell Lung Cancer, Thyroid Cancer. Supplied by Eli Lilly and Company."

Published: May 9th, 2020 7:08 AM

BRIEF-Eli Lilly Receives US FDA Approval For Retevmo

"* RETEVMO IS EXPECTED TO BE AVAILABLE FROM SPECIALTY PHARMACIES WITHIN ONE WEEK. Source text for Eikon: Further company ..."

Published: May 9th, 2020 5:22 AM

Lilly Receives US FDA Approval for Retevmo (selpercatinib), the First Therapy Specifically for ...

"... for Patients with Advanced RET-Driven Lung and Thyroid Cancers ... RET-mutant medullary thyroid cancer (MTC) who require systemic therapy, ..."

Published: May 9th, 2020 4:15 AM

Lilly Moves Ahead With Retevmo Launch In A Challenging Environment

"The company secured FDA approval for selpercatinib in RET-driven NSCLC and thyroid cancer, months ahead of the PDUFA date. Oncology ..."

Published: May 9th, 2020 3:52 AM

FDA Approves Selpercatinib for RET-Mutant NSCLC, Thyroid Cancers

"Advanced or metastatic medullary thyroid cancer in patients aged 12 or older who require systemic therapy; Advanced RET fusion-positive thyroid ..."

Published: May 9th, 2020 2:45 AM

FDA Approves First Therapy for Patients with Lung and Thyroid Cancers with a Certain Genetic ...

"Retevmo is the first therapy approved specifically for cancer patients with the RET gene alterations. "Innovations in gene-specific therapies continue to ..."

Published: May 8th, 2020 5:45 PM

'Consistent increase' observed in larger, more aggressive thyroid tumors in California

""Papillary, medullary and anaplastic histological subtypes showed increasing incidence rates, while the incidence of follicular carcinoma remained ..."

Published: May 8th, 2020 12:18 PM

Hopes high that Eva Williams will start lifeline treatment in eight weeks as she approaches 10th ...

""We spoke today with our oncologist at Alder Hey and he again re-enforced that the ONC201 trial is something to pursue, however we also discussed ..."

Published: May 7th, 2020 10:38 PM

Blueprint Medicines (BPMC) Q1 Earnings Top, Revenues Soar Y/Y

"Additionally, pralsetinib is being studied for the treatment of RET-mutant medullary thyroid carcinoma (MTC). The company is further on track to file an ..."

Published: May 6th, 2020 8:56 PM

Exelixis (EXEL) Q1 Earnings and Revenues Surpass Estimates

"... of medullary thyroid cancer generated $4.7 million in net product revenues. ... Tecentriq in patients with locally advanced or metastatic solid tumors."

Published: May 5th, 2020 7:48 PM

First ever case report of co-occurrence of hobnail variant of papillary thyroid carcinoma and ...

"Likewise, primary hyperparathyroidism with such non-medullary thyroid carcinoma is rare. The specific molecular profile of hobnail PTC (HPTC) is ..."

Published: May 4th, 2020 8:22 PM

Consensus on Thyroid Fine Needle Aspiration Biopsies During the COVID-19 Pandemic

"Conversely, as delays in diagnosis and treatment for medullary thyroid cancer can adversely affect the prognosis, it is recommended to assess ..."

Published: May 4th, 2020 6:03 PM

Turning Point Therapeutics to Host First Quarter Conference Call

"... patients with advanced or metastatic solid tumors harboring genetic alterations in MET; TPX-0046, targeting RET and SRC, which is currently being ..."

Published: May 2nd, 2020 11:22 PM

Martha Bowen

"... away peacefully in her home, surrounded by her beloved family on April 30, 2020, after a 10-year courageous battle with medullary thyroid cancer."

Published: May 2nd, 2020 1:59 PM

Quantitative bioanalytical assay for the selective RET inhibitors selpercatinib and pralsetinib in ...

"Selpercatinib and pralsetinib are potent and selective tyrosine kinase inhibitors targeting the rearranged during transfection (RET) receptor in various ..."

Published: Apr 30th, 2020 2:56 PM

Medicare rebate for rare cancer diagnosis test

""I was diagnosed 29 years ago with medullary thyroid cancer and there was no treatment for me for 28 years and my cancer progressed," she said. Last ..."

Published: Apr 30th, 2020 12:30 PM

Familial aggregation and heritability of non-medullary thyroid cancer in an Asia population: A ...

"In this nationwide cohort study, researchers evaluated the extent of familial aggregation of non-medullary thyroid cancer (NMTC) and the relative risks ..."

Published: Apr 27th, 2020 8:33 PM

COVID-19: Defer 'Bread and Butter' Procedure for Thyroid Nodules

"Exceptions for considering FNA include more urgent thyroid disease ... "Regarding medullary thyroid cancer (MTC), early diagnosis and surgery do ..."

Published: Apr 24th, 2020 11:33 AM

Bone metastases in medullary thyroid carcinoma: high morbidity and poor prognosis associated ...

"In this retrospective cohort study involving 1,060 medullary thyroid carcinoma (MTC) patients, researchers described the prevalence of bone ..."

Published: Apr 21st, 2020 8:00 PM

The Role of RET Rearrangements in Lung Cancer

"... which is formerly known as BLU-667, and selpercatinib, formerly known as LOXO-292. We entered with it being investigated in patients specifically ..."

Published: Apr 17th, 2020 5:56 PM

Most fine-needle aspiration thyroid biopsies can be 'safely delayed' during COVID-19

"Patients with suspected medullary thyroid cancer (MTC), which is relatively rare, should undergo measurement of serum calcitonin and be referred ..."

Published: Apr 10th, 2020 8:45 PM

Study Describes First Mechanism of Resistance to RET Inhibitor Selpercatinib

"... against tumors, such as non-small cell lung cancer (NSCLC) or medullary thyroid cancer (MTC), that are positive for RET fusions or mutations."

Published: Apr 10th, 2020 5:22 PM

Cancer biotech Oncoceutics loses CEO, chair and co-founder

"The first lead compound to emerge from this program is ONC201, an orally active small-molecule DRD2 antagonist. The company is supported by ..."

Published: Apr 4th, 2020 2:56 AM

Dr. Levy on Emerging Biomarkers and Corresponding Therapies in Lung Cancer

"For RET fusions, selpercatinib (LOXO-292) has shown an objective response rate (ORR) upward of 85%, adds Levy. Additionally, AMG 510 is an oral ..."

Published: Apr 2nd, 2020 8:00 PM

Rolling NDA Submitted for Pralsetinib in RET+ NSCLC Based on Topline ARROW Data

"Topline data were reported for patients with RET-mutant medullary thyroid cancer (MTC), both untreated patients and those who had previously ..."

Published: Apr 1st, 2020 8:33 PM

Blueprint Medicines Advance Pralsetinib in Multiple RET-Mutant Indications

"... RET-based oncology drug programs, including top-line data from the pralsetinib trial for patients with RET-mutant medullary thyroid cancer (MTC)."

Published: Apr 1st, 2020 5:45 PM

Blueprint Medicines' pralsetinib shows positive action in RET-altered thyroid cancer

"... announces a pipeline update including topline data from the Phase 1/2 ARROW study evaluating pralsetinib (BLU-667) in patients with solid tumors."

Published: Apr 1st, 2020 5:03 PM

Blueprint Medicines Announces the Achievement of Key Portfolio Milestones

"74% overall response rate in treatment-naive RET-mutant medullary thyroid cancer and 89% overall response rate in RET fusion-positive thyroid ..."

Published: Mar 30th, 2020 8:22 PM

Trends in Thyroid Cancer Incidence and Incidence-Based Mortality in California

"The most common histologic type was papillary thyroid carcinoma (87.8%) followed by follicular thyroid carcinoma (7.2%) and medullary thyroid ..."

Published: Mar 30th, 2020 6:00 PM

2020 Market Spotlight: Thyroid Cancer - ResearchAndMarkets.com

"Selpercatinib for Thyroid Cancer (September 29, 2019); Pralsetinib for ... Figure 7: Pralsetinib for Thyroid Cancer (June 3, 2019): Phase I/II - ARROW ..."

Published: Mar 28th, 2020 1:37 AM

UCLA, UT Southwestern join NCCN

"... he was vice president of Research and Development at Loxo Oncology, where he led the overall clinical development of selpercatinib (LOXO-292, ..."

Published: Mar 27th, 2020 5:00 PM

Thyroid Cancer Market Study, 2014-2026 - Novartis Leads Industry Sponsors With the Highest ...

"Figure 6: Selpercatinib for Thyroid Cancer (September 29, 2019): Phase I/II - LIBRETTO-001. Figure 7: Pralsetinib for Thyroid Cancer (June 3, 2019): ..."

Published: Mar 26th, 2020 9:14 PM

Why Is Exelixis (EXEL) Down 15.6% Since Last Earnings Report?

"... of medullary thyroid cancer, generated $13.8 million in net product revenues. ... inhibitor, in patients with locally advanced or metastatic solid tumors."

Published: Mar 24th, 2020 7:57 PM

Meet 'Gentle George' the boy from Bishop's Stortford asking for help to get back to school

"MEN2B is a condition which creates tumours in three areas of the body, due to overactive endocrine glands. George's diagnosis came too late to ..."

Published: Mar 22nd, 2020 4:37 PM

Amazon Boosts Overtime Pay For US Warehouse Workers

"Cometriq treats medullary thyroid cancer. Are cancer ... Vertex essentially owns the market for treating rare genetic disease cystic fibrosis (CF)."

Published: Mar 21st, 2020 9:07 AM

Four regimens receive priority review for lung cancer indications

"The agent also received priority review for RET-mutant medullary thyroid cancer and RET fusion-positive thyroid cancer. The FDA granted priority ..."

Published: Mar 21st, 2020 12:07 AM

Blueprint Medicines Corporation: An Undervalued Company With Attractive Prospects

"... cell lung cancer) and RET-mutation-positive MTC (medullary thyroid cancer). ... Currently, there are no effective approved therapies for this disease."

Published: Mar 17th, 2020 8:00 PM

Resources In Medicine Are Continually Targeted at Controlling COVID-19 Spread

"... Eli Lilly and Company to assist in identifying patients with non-small cell lung cancer and medullary thyroid cancer harboring RET variants who may ..."

Published: Mar 12th, 2020 8:00 PM

Thermo Fisher, J&J partner on next-generation sequencing diagnostic for cancer clinical trials

"... also known as LOXO-292. In that case, the test is being developed to look for RET fusions, which are the molecular target of selpercatinib, including ..."

Published: Mar 11th, 2020 3:30 AM

Exelixis, Inc. (EXEL) CEO Mike Morrissey Presents at Barclays Global Healthcare Conference ...

"And then we have a capsule formulation called COMETRIQ that is indicated for a rare form of thyroid cancer called medullary thyroid cancer. So, we're ..."

Published: Mar 10th, 2020 4:03 PM

Prediction of biochemical cure in patients with medullary thyroid cancer

"... biochemical cure in medullary thyroid cancer (MTC). Using multivariable logistic regression analysis, they determined clinical and histopathological ..."

Published: Mar 6th, 2020 11:45 PM

NCI Trials for March 2020

"A Phase II Study of LOXO-292 in Patients with RET Fusion-Positive Stage IV or Recurrent Non-Small Cell Lung Cancer (LUNG-MAP Sub-Study)."

Published: Mar 6th, 2020 9:30 PM

American Association of Endocrine Surgeons Publishes Guidelines for Thyroid Disease Surgery

"All patients diagnosed with medullary thyroid carcinoma should undergo genetic testing for a germline RET mutation, and those with multiple ..."

Published: Mar 6th, 2020 5:00 PM

Morphology of bone metastases should guide treatment in medullary thyroid cancer

""The impact of bone metastases in metastatic medullary thyroid carcinoma (MTC) on patient morbidity and prognosis has not been studied in detail ..."

Published: Mar 4th, 2020 10:03 PM

Prognostic Effect of Bone Metastases in Medullary Thyroid Cancer

"Bone metastases are present in more than a quarter of patients with metastatic medullary thyroid carcinoma (MTC), most often with an osteolytic ..."

Published: Mar 4th, 2020 4:48 PM

Thyroid Cancer Drugs Market Forecasts, 2020-2030 - Increasing Use of Combination Drugs Spurs ...

"For example, Vandetanib (Caprelsa) and Cabozantinib (Cometriq) are targeted therapies used to treat advanced medullary thyroid cancer (MTC)."

Published: Feb 29th, 2020 5:56 PM

Boy with a fatal form of brain cancer to pursue trial in USA

"In a desperate bid to find options, Ms Hatzl has also considered a drug called ONC201, which has been shown to kill tumour cells in studies overseas, ..."

Published: Feb 29th, 2020 2:33 AM

George Labonte is running to show other survivors that cancer can't stop them

"In early 2016, I was diagnosed with a rare and incurable cancer called Medullary Thyroid Carcinoma. At the time, I wasn't sure if I would live out the ..."

Published: Feb 27th, 2020 11:11 PM

Exelixis: Potential Catalysts Ahead For This Mid-Cap Oncology Company

"Another drug, Cometriq capsules, has been approved by the FDA in progressive and metastatic medullary thyroid cancer indication. The active ..."

Published: Feb 26th, 2020 8:41 PM

Exelixis (EXEL) Beats on Earnings, Misses on Sales in Q4

"Cometriq (cabozantinib capsules), for the treatment of medullary thyroid cancer, generated $13.8 million in net product revenues. Exelixis also earned ..."

Published: Feb 26th, 2020 2:00 AM

Exelixis Announces First 100 Patients Enrolled in Phase 3 COSMIC-311 Pivotal Trial of ...

""Given the encouraging clinical activity observed for cabozantinib in phase 1 and 2 trials in differentiated thyroid cancer, and the poor prognosis for ..."

Published: Feb 24th, 2020 8:56 PM

Repurposing Astellas' and Novartis' leukemia drugs in resistant lung cancer

"Blueprint Medicines is studying a combination of Tagrisso with its RET inhibitor BLU-667 in patients with advanced EGFR-mutant NSCLC who also ..."

Published: Feb 24th, 2020 7:03 PM

Predictive Markers for mCRC

"We know there is the BLU-667 compound and there's a LOXO-292 compound that's currently out there being used for thyroid and lung cancer. And the ..."

Published: Feb 20th, 2020 7:07 PM

Turning Point Therapeutics Names Siegfried Reich as Executive Vice President and Chief ...

"The company's pipeline of drug candidates also includes TPX-0022, ... or metastatic solid tumors harboring genetic alterations in MET; TPX-0046, ..."

Published: Feb 14th, 2020 9:25 PM

Blueprint Medicines (BPMC) Q4 Loss Narrows, Revenues Top Mark

"Blueprint Medicines initiated the rolling submission of NDA to the FDA for its precision therapy pralsetinib to address the RET fusion-positive ..."

Published: Feb 14th, 2020 1:03 AM

Blueprint Medicines Corporation's (BPMC) CEO Jeff Albers on Q4 2019 Results - Earnings Call ...

"This morning in addition to financial results for 2019, we will highlight key value drivers for Blueprint Medicines in 2020, discuss topline pralsetinib in ..."

Published: Feb 13th, 2020 7:15 PM

EU Speedy Review Success For Kite But Not For Lilly

"... therapy, will in the end be fast-tracked at the European Medicines Agency. Lilly failed to secure the speedy review it was seeking for selpercatinib ..."

Published: Feb 12th, 2020 8:56 PM

Stock To Watch: Blueprint Medicines (BPMC)

"A New Drug Application for Pralsetinib for previously treated RET-mutant medullary thyroid cancer is expected to be filed with the FDA in the second ..."

Published: Feb 11th, 2020 4:48 PM

Interpace Biosciences Announces Another Pricing improvement for its Thyroid Assay

"... the two most common forms of thyroid cancer, as well as Medullary Thyroid Carcinoma. ThyraMIR is the first microRNA gene expression classifier."

Published: Feb 11th, 2020 4:03 PM

Exelixis bounces back with new prostate cancer data

"Exelixis bounces back with new prostate cancer data ... as a treatment for progressive, metastatic medullary thyroid cancer in the US and Europe."

Published: Feb 11th, 2020 1:48 AM

Testing for RET Fusions in NSCLC Remains Critical as Targeted Therapy BLU-667 Evolves

"The selective RET inhibitor BLU-667 has demonstrated durable responses in patients with RET fusion-positive lung cancer in the phase I ARROW ..."

Published: Feb 8th, 2020 7:03 PM

A Look Back at FDA News from January 2020

"... Review to Selpercatinib in RET Fusion+ NSCLC and Thyroid Cancer ... non-small cell lung cancer, RET-mutant medullary thyroid cancer, and RET ..."

Published: Feb 5th, 2020 1:48 AM

Jennifer Jeske, 47

"The family appreciates memorials to ThyCa Donation, Attn: Medullary Thyroid Cancer Research Fund, P.O. Box 1102, Olney, Maryland, 20830-1102."

Published: Feb 4th, 2020 8:00 PM

Investigators Seek New Standard in RET Fusion-Positive NSCLC

"Investigators hope selpercatinib (LOXO-292), a highly selective RET inhibitor, will demonstrate potential as a new standard of care (SOC) for patients ..."

Published: Feb 4th, 2020 7:48 PM

Takeda unveils profit surprise on Shire integration-and no US Natpara supply till 2021

"Takeda doesn't expect any Natpara sales in the U.S. into fiscal 2020 ending in March 2021, as discussions with FDA to resume supply after a recent ..."

Published: Jan 31st, 2020 11:00 PM

FDA Grants Priority Review to Selpercatinib for Lung and Thyroid Cancer Subsets

"The application is based on findings from the phase I/II LIBRETTO-001 trial, which evaluated selpercatinib in RET-altered NSCLC and thyroid cancers."

Published: Jan 30th, 2020 9:50 PM

Lilly's NDA for Selpercatinib Gets FDA's Priority Review

"... non-small cell lung cancer (NSCLC), RET-mutant medullary thyroid cancer ... Many industry players are adopting this method to bring new cancer ..."

Published: Jan 30th, 2020 9:41 PM

Lilly's NDA for Selpercatinib Gets FDA's Priority Review

"The company plans to complete the NDA submission for pralsetinib in the first quarter of 2020 to treat NSCLC while the same for the MTC indication is ..."

Published: Jan 30th, 2020 5:33 PM

Lilly keeps ahead of Blueprint with swift FDA review for selpercatinib

"... review for selpercatinib (LOXO-292) in RET fusion-positive non-small cell lung cancer (NSCLC), medullary thyroid cancer (MTC) and thyroid cancer ..."

Published: Jan 30th, 2020 12:18 PM

Lilly's selpercatinib gets FDA priority review for lung and thyroid cancers

"Lilly's selpercatinib gets FDA priority review for lung and thyroid cancers ... fusion-positive thyroid cancer, and RET-mutant medullary thyroid cancer ..."

Published: Jan 30th, 2020 7:54 AM

CABA Hits New High, IMMP On Watch, SBPH Drops CATALYST

"... RET-mutant medullary thyroid cancer and RET fusion-positive thyroid cancer has been granted priority review by the FDA - with a decision expected ..."

Published: Jan 29th, 2020 10:37 PM

FDA grants priority review to selpercatinib for RET-altered NSCLC, thyroid cancer

"The FDA granted priority review to selpercatinib for the treatment of advanced RET fusion-positive non-small cell lung cancer, RET-mutant medullary ..."

Published: Jan 29th, 2020 10:03 PM

FDA Grants Priority Review to Selpercatinib in RET Fusion+ NSCLC and Thyroid Cancer

"The New Drug Application (NDA) for selpercatinib (LOXO-292) was granted FDA Priority Review for the treatment of patients with advanced RET ..."

Published: Jan 29th, 2020 6:24 PM

Bay Street Likely To Open Higher

"Eli Lilly has applied for approval of the treatment in three different types of tumors with altered RET: non-small-cell lung cancer, medullary thyroid ..."

Published: Jan 29th, 2020 6:18 PM

Thyroid Cancer Symptom: A Lump On This Body Part Could Be An Early Warning Sign

"Thyroid Cancer Symptom: A Lump On This Body Part Could Be An Early Warning ... At its initial stages, thyroid cancer might not exhibit any symptoms. ... syndromes including Cowden's syndrome, familial medullary thyroid cancer, ..."

Published: Jan 29th, 2020 4:48 PM

Lilly's selpercatinib application nabs accelerated review in US

"... advanced RET fusion-positive non-small cell lung cancer (NSCLC), RET-mutant medullary thyroid cancer and RET fusion-positive thyroid cancer."

Published: Jan 29th, 2020 4:37 PM

Lilly Receives FDA Priority Review for the Selpercatinib New Drug Application

"... RET fusion-positive non-small cell lung cancer (NSCLC), RET-mutant medullary thyroid cancer (MTC) and RET fusion-positive thyroid cancer."

Published: Jan 28th, 2020 1:15 AM

National Brain Tumor Society Backs Oncoceutics' Phase II Trial for Subset of High-Grade Gliomas

"ONC201 is the first imipridone dopamine receptor D2 antagonist (DRD2) that treats high-grade glioma by selectively targeting G protein-coupled ..."

Published: Jan 24th, 2020 11:33 PM

Patients with Hypoparathyroidism Warned of Extended NATPARA Recall

"NATPARA was voluntarily pulled off the market by the manufacturer (Takeda) after small particles of rubber were found in some samples of the ..."

Published: Jan 24th, 2020 9:52 AM

Trial drug ONC201 hopes for wife of Boro coach Graeme Lee

"FOOTBALL fans in the North-East are being urged to show their support for the wife of a former player. Graeme Lee started his career with Hartlepool ..."

Published: Jan 24th, 2020 5:00 AM

CStone successfully hosted the first US R&D Day in New York

"A total of five NDA submissions in Mainland China and Taiwan for CS1001, an anti-PD-L1 monoclonal antibody; pralsetinib, a RET inhibitor; and ..."

Published: Jan 23rd, 2020 7:02 PM

Turning Point Therapeutics Names Garry Nicholson to Its Board of Directors

"The company's pipeline of drug candidates also includes TPX-0022, ... or metastatic solid tumors harboring genetic alterations in MET; TPX-0046, ..."

Published: Jan 22nd, 2020 2:00 AM

Blueprint Medicines Announces Proposed Public Offering of Shares of Common Stock

"... to fund clinical trials for pralsetinib in RET-driven cancers, including its Phase 3 AcceleRET Lung clinical trial for pralsetinib in first-line RET-altered ..."

Published: Jan 20th, 2020 11:00 PM

Pralsetinib effective, safe for RET fusion-positive NSCLC

"Approximately 90% of patients with advanced medullary thyroid cancer have RET mutations. The ongoing phase 1/phase 2 ARROW trial evaluated ..."

Published: Jan 20th, 2020 4:03 PM

Lilly will aim for one $1bn-$5bn deal per quarter in 2020

"Another promising candidate Lilly gained from the Loxo takeover is LOXO-292, which is currently being studied in a phase 1/2 trial for non-small cell ..."

Published: Jan 17th, 2020 4:15 AM

FDA approves Ozempic for cardiovascular risk reduction in adults with type 2 diabetes and ...

"It is not known if Ozempic will cause thyroid tumors or a type of thyroid cancer called medullary thyroid carcinoma (MTC) in people.Do not use ..."

Published: Jan 17th, 2020 12:07 AM

A venture firm warms to funding neuroscience

"But only three - the cell therapy companies Kyverna, Tmunity, and Arsenal Biosciences - are publicly known. Any hints? Unlock this article by ..."

Published: Jan 15th, 2020 5:00 PM

Tmunity Announces First Patient Dosed in Phase 1 Clinical Trial with CART-TnMUC1

"Tmunity Therapeutics, Inc., a private clinical-stage biotherapeutics company focused on saving and improving lives by delivering the full potential of ..."

Published: Jan 13th, 2020 6:52 PM

Turning Point Therapeutics Announces Program Updates and Milestones for 2020

"Multiple RET-Positive Patients with Solvent-Front Mutations Previously Treated with Other Investigational RET Inhibitors Dosed with TPX-0046"

Published: Jan 12th, 2020 2:00 AM

Thyroid cancer is somewhat mysterious

"Thyroid cancer is one of the rarer cancers and not in the list of the top 10 ... The medullary thyroid cancer (MTC) comes from a different cell in the ..."

Published: Jan 11th, 2020 4:26 AM

GIST kissed ahead of V-Day PDUFA, Blueprint design plan for Ayvakit goes 'fourth'

"Blueprint also plans to submit, in the second quarter, an NDA to the FDA for pralsetinib for medullary thyroid cancer previously treated with an ..."

Published: Jan 11th, 2020 12:52 AM

Pralsetinib Achieves Durable Responses in Patients With RET+ NSCLC

"Pralsetinib (BLU-667), a highly-selected RET inhibitor, achieved a favorable overall response rate (ORR) with prolonged durability in patients with ..."

Published: Jan 10th, 2020 10:05 PM

Top-Line Data Reported for Pralsetinib in Patients with RET Fusion-Positive NSCLC

"... to the FDA for pralsetinib for the treatment of patients with medullary thyroid cancer (MTC) previously treated with an approved multikinase inhibitor."

Published: Jan 10th, 2020 2:56 AM

Turning Point Therapeutics Announces Management Transition

"The company's pipeline of drug candidates also includes TPX-0022, ... and TPX-0046, targeting RET and SRC, which is currently being studied in a ..."

Published: Jan 9th, 2020 7:37 PM

Blueprint Medicines Posts Data From NSCLC Study on Pralsetinib

"Notably, pralsetinib is also being studied for RET-mutant medullary thyroid carcinoma (MTC). The company plans to complete the NDA submission for ..."

Published: Jan 9th, 2020 7:36 PM

Blueprint Medicines Posts Data From NSCLC Study on Pralsetinib

"The ARROW study evaluated once-daily oral, pralsetinib in 80 patients with RET fusion-positive NSCLC who received prior treatment with ..."

Published: Jan 9th, 2020 4:15 PM

Thyroid Cancer Drug Market Had A Booming Decade || Celgene Corporation, AstraZeneca ...

"Global thyroid cancer drug market is rise gradually to an estimated value of ... thyroid cancer, Follicular thyroid cancer, Hurthle cell cancer, Medullary ..."

Published: Jan 9th, 2020 2:22 PM

Turning Point (TPTX) Marches Ahead, Awaits TRIDENT-1 Data Update In 2020

"Next up in the pipeline TPX-0046 is under phase I/II study for the treatment of advanced solid tumors with abnormal RET genes. Another clinical drug ..."

Published: Jan 9th, 2020 4:15 AM

Blueprint Reports High Response Rates From Lung Cancer Patients in Early Pralsetinib Trials

"In the second quarter, the company plans to file an NDA for the medullary thyroid cancer indication. RET fusions appear in approximately 1 to 2 ..."

Published: Jan 8th, 2020 10:15 PM

Lilly looms over Blueprint as the biotech files targeted cancer drug

"The biotech also intends to ask regulators to approve pralsetinib as a treatment for medullary thyroid cancer, with an application planned for the ..."

Published: Jan 8th, 2020 8:36 PM

Blueprint throws down targeted therapy gauntlet with new lung cancer data, FDA submission

"Its most advanced competitor is Indianapolis-based Eli Lilly's Loxo Oncology division, whose RET inhibitor LOXO-292 (selpercatinib) has also shown ..."

Published: Jan 8th, 2020 8:33 PM

Blueprint throws down targeted therapy gauntlet with new lung cancer data, FDA submission

"... Medicines said Wednesday that it had started a rolling submission to the Food and Drug Administration for the drug BLU-667 (pralsetinib), based on ..."

Published: Jan 8th, 2020 12:37 AM

Orphan Drugs Market Growth Strategies by 2027 with Leading Key Players Takeda ...

"Based on disease the market is segmented into Hodgkin lymphoma, ... 1 (GD1), Metastatic medullary thyroid carcinoma, Advanced gastric cancer or ..."

Published: Jan 7th, 2020 7:03 PM

Thyroid nodules: diagnostic evaluation based on thyroid cancer risk assessment

"We focus on the concept of risk assessment for thyroid cancer at different stages of the diagnostic pathway for ...... MTC-medullary thyroid cancer."

Published: Jan 4th, 2020 5:00 PM

Plea for access to new drug for girl diagnosed with brain cancer

"The new drug, ONC201, is being trialled in the USA and Germany but not ... ONC201 has been shown to kill tumour cells in studies overseas but the ..."

Published: Jan 2nd, 2020 8:00 PM

New faces at Merus, Rubius Therapeutics and Titan Pharmaceuticals

"She joins from Tmunity Therapeutics, where she also served as chief medical ... At Tmunity, she was responsible for the development of the company's ..."

Published: Jan 1st, 2020 8:00 PM

Video Series Offers Support to Cancer Caregivers

"The American Cancer Society (ACS) created a video series for caregiver support to address their most-asked ... RET-Mutant Medullary Thyroid Cancer"

Published: Dec 31st, 2019 11:56 PM

CURE's Clinical Trial Corner: December 2019

"The trial will enroll 400 patients with advanced or metastatic RET-mutant medullary thyroid cancer who have received no prior systemic therapy for ..."

Published: Dec 31st, 2019 2:00 AM

Lilly opens Phase III trial of highly targeted Loxo drug in thyroid cancer

""This Phase III trial of selpercatinib in patients advanced or metastatic ... The thyroid cancer trial is randomizing patients to receive selpercatinib or ..."

Published: Dec 30th, 2019 9:41 PM

Eli Lilly Opens Phase III Trial for RET-Mutant Medullary Thyroid Cancer

"Selpercatinib is an orally administered drug in clinical development for cancers with abnormalities in the rearranged during transfection (RET) kinase."

Published: Dec 30th, 2019 5:56 PM

Lilly launches late-stage study of LOXO-292 in medullary thyroid cancer

"Eli Lilly (NYSE:LLY) initiates a Phase 3 clinical trial, LIBRETTO-531, evaluating selpercatinib (LOXO-292) in previously untreated patients with ..."

Published: Dec 27th, 2019 11:56 PM

First Randomized Phase III Trial Opens for Treatment-Naive RET Fusion-Positive NSCLC

"Breakthrough designations in RET fusion-positive NSCLC, RET-mutant medullary thyroid cancer (MTC), and RETfusion-positive thyroid cancers have ..."

Published: Dec 25th, 2019 6:19 PM

Thyroid Cancer Treatment Market Will Generate New Growth Opportunities in the Next Upcoming ...

"Follicular cancer, medullary cancer, and Anaplastic cancer are different types of thyroid cancers. The treatments which is available for thyroid cancer ..."

Published: Dec 23rd, 2019 6:30 PM

New medical chief at Rubius Therapeutics

"Dr. Coughlin joins Rubius from Tmunity Therapeutics, where she served as CMO and was responsible for the development of Tmunity's CAR-T and ..."

Published: Dec 23rd, 2019 6:02 PM

Rubius Therapeutics Appoints Christina Coughlin, MD, Ph.D., as Chief Medical Officer

"A trained oncologist and immunologist, Dr. Coughlin joins Rubius from Tmunity Therapeutics, Inc., where she served as chief medical officer and was ..."

Published: Dec 18th, 2019 8:56 PM

Natpar(a): A Case in Point for Rare Disease Drugs?

"While the recent recall of injectable recombinant parathyroid hormone (PTH) (Natpara, Takeda) in the United States has grabbed the headlines, the ..."

Published: Dec 18th, 2019 2:56 AM

Eli Lilly Shines With BTK Inhibitor Drug In Treating B-Cell Leukemias And Lymphomas

"It used its drug LOXO-305 to treat B-Cell Leukemias and Lymphomas. ... Eli Lilly's other product from the acquisition of LOXO, known as LOXO-292, ..."

Published: Dec 17th, 2019 10:15 PM

RET Inhibitor Trial Updates at ASCO and ESMO

"... the BLU-667 agent in medullary thyroid cancer predominantly. That, again, showed extremely good response rate, with a total response rate, overall ..."

Published: Dec 17th, 2019 10:03 PM

ESMO 2019 LIBRETTO-001 Trial Updates

"... an update of the LIBRETTO-001 study for differentiated thyroid cancer and medullary thyroid cancer was presented, and the partial response was in ..."

Published: Dec 17th, 2019 9:52 PM

LOXO-292 in Patients With RET-Fusion Lung Cancer

"LOXO-292 in Patients With RET-Fusion Lung Cancer. Insights From: Jacob Sands, MD, Dana-Farber Cancer Institute; Benjamin Besse, MD, PhD, ..."

Published: Dec 17th, 2019 7:05 PM

Turning Point Therapeutics to Participate in 38th Annual JP Morgan Healthcare Conference

"The company's pipeline of drug candidates also includes TPX-0022, ... and TPX-0046, targeting RET and SRC, which is currently being studied in a ..."

Published: Dec 16th, 2019 10:03 PM

Top M&A Deals in 2019

"LOXO-292, a first-in-class oral RET inhibitor that has been granted Breakthrough Therapy designation by the FDA for three indications, with an initial ..."

Published: Dec 13th, 2019 8:14 PM

Blueprint Medicines (BPMC) Up More Than 30% YTD: Here's Why

"Pralsetinib (formerly BLU-667) in being studied in the phase I/II ARROW study evaluating previously-treated patients with receptor tyrosine RET-fusion ..."

Published: Dec 13th, 2019 7:37 PM

Blueprint Medicines (BPMC) Up More Than 30% YTD: Here's Why

"... is being evaluated in several late-stage studies for cancer indications. ... lung cancer (NSCLC) and RET-mutant medullary thyroid carcinoma (MTC)."

Published: Dec 13th, 2019 5:00 PM

Pharma Stock Roundup: MRK, SNY to Buy Cancer Firms, LLY Starts New Lung Cancer Study

"Lilly Initiates Lung Cancer Study on Selpercatinib: Lilly began a phase III study to evaluate its oral RET inhibitor, selpercatinib/LOXO-292in previously ..."

Published: Dec 12th, 2019 8:33 PM

Lilly Initiates Phase III Lung Cancer Study on RET Inhibitor

"Eli Lilly and Company LLY initiated a phase III LIBRETTO-431 study (NCT04194944) on its oral RET inhibitor, selpercatinib (LOXO-292), ..."

Published: Dec 12th, 2019 7:03 PM

Lilly Initiates Phase III Lung Cancer Study on RET Inhibitor

"Eli Lilly and Company LLY initiated a phase III LIBRETTO-431 study (NCT04194944) on its oral RET inhibitor, selpercatinib (LOXO-292), ..."

Published: Dec 12th, 2019 2:33 PM

Lilly launches first of its kind trial for RET fusion-positive NSCLC

"The LIBRETTO-431 clinical trial is assessing selpercatinib, also known as LOXO-292, for treatment-naiive RET fusion-positive non-small cell lung ..."

Published: Dec 12th, 2019 2:11 AM

Eli Lilly Opens Phase III Trial for RET Fusion-Positive Non-Small Cell Lung Cancer Drug

"The trial will examine the effects of selpercatinib (LOXO-292) in cancer patients who have had no prior treatment for their condition. Participants will be ..."

Published: Dec 11th, 2019 10:48 PM

Lilly Opens First Ever Randomized Phase 3 Clinical Trial in Treatment-Naiive RET Fusion-Positive ...

"Selpercatinib has received breakthrough designations in RET fusion-positive NSCLC, RET-mutant medullary thyroid cancer (MTC) and RET ..."

Published: Dec 11th, 2019 4:48 PM

Lilly opens late-stage RET fusion-positive NSCLC study

"Eli Lilly (NYSE:LLY) launches the Phase 3 LIBRETTO-431 clinical trial for selpercatinib, also known as LOXO-292, for treatment-naiive RET ..."

Published: Dec 11th, 2019 7:39 AM

A Multicenter, Randomized, Open-Label, Phase 3 Trial Comparing LOXO-292 to Platinum-Based ...

"A Multicenter, Randomized, Open-Label, Phase 3 Trial Comparing LOXO-292 to Platinum-Based and Pemetrexed Therapy with or without ..."

Published: Dec 10th, 2019 11:41 AM

HR and Talent Acquisition Manager

"Tmunity Therapeutics is seeking a strong talent acquisition and human resources manager to manage..."

Published: Dec 9th, 2019 8:00 PM

Thermo Fisher (TMO) at a 52-Week High: What's Driving It?

"... Test to identify certain non-small cell lung cancer and thyroid cancer patients who may be treated with Lilly's investigational therapy, LOXO-292."

Published: Dec 9th, 2019 3:40 PM

Executive of the Year: Josh Bilenker, Loxo Oncology

"Another, known as selpercatinib, drew Eli Lilly to negotiate what became an $8 billion buyout of Loxo in the opening days of 2019. Measured from the ..."

Published: Dec 4th, 2019 1:03 AM

Woman with 100 cancerous tumours in her lungs refuses to find out prognosis

"A woman who was diagnosed with cancer when she was just 21 was ... result, but an ultrasound revealed Ashley had medullary thyroid cancer."

Published: Dec 2nd, 2019 10:03 PM

Potential Gene Mutation May Help to Identify Familial Thyroid Cancer

""Thyroid cancer is common and on the rise, and hereditary non-medullary thyroid cancers account for 6%-10% of cases," lead study author Darrin ..."

Published: Dec 2nd, 2019 8:33 PM

Drug Recall in US Causes Hypoparathyroid Patients Extreme Hardship

"The recall of injectable recombinant parathyroid hormone (PTH) (Natpara, Takeda) in the United States over safety concerns about the product is ..."

Published: Nov 28th, 2019 4:25 AM

Wichita nonprofit trying to save clinical trial helping young brain cancer patients

"But that grim outlook is different with the drug ONC201. Ward is among the patients participating in a clinical trial for the drug. He says, statistically, he ..."

Published: Nov 27th, 2019 7:26 PM

Treatments Improve PFS in Thyroid Cancer

"Treatments Improve PFS in Thyroid Cancer ... are another 2 drugs that can delay the progression of disease in patients with medullary thyroid cancer."

Published: Nov 27th, 2019 1:03 AM

Molecular Testing Moves in Front of Systemic Treatment for Certain Thyroid Cancers

"Upfront biomarker testing is now recommended for patients with differentiated thyroid cancer (DTC) or medullary thyroid cancer (MTC) since targeted ..."

Published: Nov 22nd, 2019 10:48 PM

Kansas family hoping for miracle for 5-year-old with inoperable cancer

""We're narrowing in on this ONC201 trial that is out there because it's the only thing that we can see that may give us a shred of hope," Stacey said."

Published: Nov 22nd, 2019 4:13 AM

Olathe family hoping for miracle for 5-year-old with inoperable cancer

""We're narrowing in on this ONC201 trial that is out there because it's the only thing that we can see that may give us a shred of hope," Stacey Sands ..."

Published: Nov 21st, 2019 1:48 AM

LIBRETTO-001 Regimen Overview

"In contrast, selpercatinib is a selective RET inhibitor that very meaningfully hits RET but avoids these other targets that can result in adverse effects in ..."

Published: Nov 21st, 2019 1:37 AM

RET Testing in Papillary and Medullary Thyroid Cancer

"The same is true in medullary thyroid cancer, where both vandetanib and cabozantinib work in patients both with and without RET mutations."

Published: Nov 21st, 2019 1:26 AM

RET Treatment: Novel Compounds to Replace Current TKIs

"Marcia Brose, MD, PhD: In medullary thyroid cancer we have these 2 agents. As I just mentioned in the toxicity discussion, these clearly are not agents ..."

Published: Nov 20th, 2019 7:03 PM

Researchers identify new gene mutation in familial thyroid cancers

""Thyroid cancer is common and on the rise, and hereditary non-medullary thyroid cancers account for six to ten percent of cases," said Bann. "Prior to ..."

Published: Nov 20th, 2019 2:45 AM

RET Fusion, Point Mutation, and Signaling

"It is often found in papillary thyroid cancer in that form. That's the contrast with medullary thyroid cancer, where you'll actually have point mutations."

Published: Nov 20th, 2019 12:41 AM

'Stay tuned:' Neoadjuvant therapy in thyroid cancer still needs research

"... with medullary thyroid cancer who have RET mutations and in those with RET-fusion papillary, poorly differentiated and anaplastic thyroid cancer."

Published: Nov 19th, 2019 7:03 PM

Investigational Drug Shows Promise in Patients with RET-Altered Cancers

"Patients with RET-fusion-positive non-small cell lung cancer (NSCLC) had a high response to LOXO-292 (selpercatinib), according to findings from ..."

Published: Nov 18th, 2019 7:03 PM

How gene-edited white blood cells are helping fight cancer

"... scientists from the University of Pennsylvania, the Parker Institute for Cancer Immunotherapy in San Francisco and Tmunity Therapeutics, a biotech ..."

Published: Nov 12th, 2019 6:33 PM

Turning Point Therapeutics Initiates Phase 1/2 Clinical Study of Repotrectinib in Pediatric Patients

"The company's pipeline of drug candidates also includes TPX-0022, ... and TPX-0046, targeting RET and SRC, which is currently being studied in a ..."

Published: Nov 12th, 2019 3:39 AM

Dr. Offin on Targeted Agents in MET- and RET-Altered NSCLC

"Encouragingly, selpercatinib (formerly LOXO-292) and BLU-667 have shown greater tolerability. Although selpercatinib has shown a slightly higher ..."

Published: Nov 11th, 2019 8:04 PM

Orphan Drug Recall Leaves Patients in the Lurch

"And since Takeda's Natpara (parathyroid hormone) injection is the only effective treatment for Shelton, she knew when she received an official Takeda ..."

Published: Nov 10th, 2019 10:02 AM

Current Concepts in Head and Neck Surgery

"Incorporate a multidisciplinary approach in the management of tumors of ... well differentiated/de-differentiated/anaplastic/medullary thyroid cancers, ..."

Published: Nov 10th, 2019 5:08 AM

Biological activity of weekly ONC201 in adult recurrent glioblastoma patients

"ONC201 is a dopamine receptor D2 (DRD2) antagonist that penetrates the blood brain barrier. ONC201 efficacy has been shown in glioblastoma ..."

Published: Nov 9th, 2019 8:32 AM

Thyroid cancer at a glance

"There are four types of thyroid cancer: papillary, follicular, medullary and anaplastic. How serious the illness is and the kind of treatment you get ..."

Published: Nov 8th, 2019 9:17 PM

Next-Generation Sequencing Sets Sights On Rare Mutations in Lung Cancer

"With selpercatinib, as well as BLU-667, there is hope for a better targetable option here. Both medications are well tolerated. Selpercatinib had a bit of ..."

Published: Nov 7th, 2019 3:16 PM

Early Results from First-In-US Trial of CRISPR-Edited Immune Cells for Cancer Patients Suggest ...

"Penn is conducting the ongoing study in cooperation with the Parker Institute for Cancer Immunotherapy (PICI) and Tmunity Therapeutics. "This trial is ..."

Published: Nov 7th, 2019 1:30 PM

Tmunity Raises $75 Million in Series B funding for T-cell Therapies Advancement

"In a new development that must have come as a big boost to the company and the wider industry, Tmunity has managed to raise as much as $75 ..."

Published: Nov 7th, 2019 9:34 AM

InDEPTH with Brad Byrd: Sudden Recall

"Recently, the drug Natpara was recalled by pharmaceutical company, Takada. It's used to treat hypoparathyroidism. Sandy Keneipp, who lives in ..."

Published: Nov 7th, 2019 8:47 AM

Tmunity Therapeutics' $75 million financing tops recent funding news in Philadelphia

"Philadelphia-based therapeutics and genetics company Tmunity Therapeutics has secured $75 million in Series B funding, according to company ..."

Published: Nov 7th, 2019 4:54 AM

Another Biotech Gets Big Funding

"Westlake Village BioPartners' first investment, a T-Cell therapy startup called Tmunity Therapeutics, raised $75 million in Series B financing, the ..."

Published: Nov 6th, 2019 10:15 PM

Advancing the Treatment of Thyroid Cancer With Targeted Therapies

"Advancing the Treatment of Thyroid Cancer With Targeted Therapies ... or well-differentiated metastatic thyroid cancer, and also for medullary thyroid ..."

Published: Nov 6th, 2019 9:16 PM

Research underway on essential genes in medullary thyroid cancer

""If we were to understand the proteome changes during medullary thyroid cancer tumor development, we thought that perhaps we could target it," ..."

Published: Nov 6th, 2019 7:41 PM

Doctors try CRISPR gene editing for cancer, a 1st in the US

"... by the University of Pennsylvania, the Parker Institute for Cancer Immunotherapy in San Francisco, and a biotech company, Tmunity Therapeutics."

Published: Nov 6th, 2019 7:01 PM

Crispr Takes Its First Steps in Editing Genes to Fight Cancer

"The research was paid for by the Parker Institute for Cancer Immunotherapy and the company Tmunity. Some members of the research team, but not ..."

Published: Nov 6th, 2019 6:30 PM

Biotherapeutics company enters partnership to design future clinical programs

"East Norriton-based Tmunity Therapeutics, a private clinical-stage biotherapeutics company focused on next-generation T-cell immunotherapy, ..."

Published: Nov 1st, 2019 6:41 PM

FiercePharmaAsia-Takeda's rare disease decline; Astellas-Pandion diabetes deal; I-Mab's ...

"... previous two quarters, thanks to competition facing Shire's legacy hemophilia drugs and a surprise U.S. recall of Natpara. Astellas is paying Pandion ..."

Published: Nov 1st, 2019 3:18 AM

Tmunity Secures $75M in Series B Financing

"Tmunity Therapeutics, a Philadelphia, PA-based T-cell immunotherapy company, closed a $75m Series B financing. The round was led by ..."

Published: Nov 1st, 2019 1:26 AM

Andreessen Horowitz Leads $75 Million Financing for Tmunity Therapeutics

"Tmunity Therapeutics Inc. has raised a $75 million Series B funding led by Andreessen Horowitz to propel a series of cancer-fighting cellular therapies ..."

Published: Oct 31st, 2019 7:48 PM

Exelixis (EXEL) Q3 Earnings Beat on Strong Cabometyx Sales

"Cometriq (cabozantinib capsules), for the treatment of medullary thyroid cancer, generated $4.4 million in net product revenues. Total collaboration ..."

Published: Oct 31st, 2019 6:30 PM

Tmunity aims to be the next big biotech win for Philly, raising $75 million from Silicon Valley

"Tmunity Therapeutics, a four-year-old firm developing cancer treatments based on University of Pennsylvania T-cell immunotherapy, has raised ..."

Published: Oct 31st, 2019 5:49 PM

Hemophilia rivalry eats away at post-Shire Takeda-and its Natpara recall bites, too

"Before Takeda scored its $59 billion Shire takeover, critics pointed out threats to the Irish drugmaker's bread-and-butter hemophilia franchise."

Published: Oct 31st, 2019 4:03 PM

Oz Azam beefs up Tmunity's total raise to $231M as they steer toward human data in the drive to ...

"Oz Azam beefs up Tmunity's total raise to $231M as they steer toward human data in the drive to cell therapy 2.0. The CEO of Tmunity believes that if ..."

Published: Oct 31st, 2019 3:52 PM

Andreessen Horowitz leads $75M round for Tmunity as it eyes phase 2 studies for 2021

"The new funding will bankroll R&D, clinical development and manufacturing both for the vectors that deliver Tmunity's treatments as well as the cell ..."

Published: Oct 30th, 2019 8:00 PM

Early Detection Impacts Treatment Decisions in Thyroid Cancers

"Either way, the role of early detection of thyroid cancer is of utmost ... such as medullary thyroid cancer (MTC), differentiated thyroid cancer (DTC), and ..."

Published: Oct 29th, 2019 4:00 PM

Interpace to Present Data at the ATA Annual Meeting

"... other providers who focus on the diagnosis and treatment of thyroid cancer. ... "Molecular diagnosis of medullary thyroid carcinoma by NGS mutation ..."

Published: Oct 25th, 2019 3:52 PM

Don't Sleep on These 2 Pharmaceutical Stocks

"The acquisition also brought Eli Lilly LOXO-292, a promising cancer treatment that could launch next year, and LOXO-305, another cancer treatment ..."

Published: Oct 22nd, 2019 2:56 PM

Eli Lilly Reports Earnings Tomorrow. Here's What to Expect.

"The company has reported some promising data in recent months, including a strong response rate for its drug LOXO-292 in some lung cancer ..."

Published: Oct 21st, 2019 8:33 PM

Bernie urges FDA to swiftly resolve drug recall

"In response to Takeda Pharmaceuticals recalling Natpara, a lifesaving drug used to manage blood calcium levels for people with a rare condition ..."

Published: Oct 21st, 2019 11:22 AM

Vietnamese surgeons succeed in operating on three-year-old with thyroid cancer

"Vietnamese surgeons succeed in operating on three-year-old with thyroid ... on an three-year-old kid with metastasized medullary thyroid cancer."

Published: Oct 19th, 2019 12:18 AM

Bernie Sanders, 2 other lawmakers urge FDA to resolve Natpara shortage

"Takeda recalled Natpara, a treatment for a rare, but potentially fatal calcium-depleting disease, Sept. 5 after it discovered rubber particles in the vials ..."

Published: Oct 18th, 2019 11:02 PM

Leahy, Sanders, Welch Urge FDA to Swiftly Resolve Critical Drug Recall

"Peter Welch (D-Vt.) urged the Food and Drug Administration (FDA) to swiftly resolve the recall of Natpara, a lifesaving drug used to manage blood ..."

Published: Oct 18th, 2019 8:56 PM

LIBRETTO-001: RET-Fusion Positive Metastatic NSCLC

"LOXO-292 is a very selective RET inhibitor. Based on recent phase I/II studies, among over 100 patients with advanced-stage, RET fusion-positive ..."

Published: Oct 18th, 2019 4:48 PM

Ipsen adds Blueprint's FOP rare disease drug to pipeline for $535m

"Blueprint also develops cancer drugs. It is developing avapritinib for certain gastrointestinal tumours, and its BLU-667 is in development for cancers ..."

Published: Oct 14th, 2019 9:24 PM

Blueprint Medicines' Avapritinib Grows to Curb Revenue Reliance

"... cancer (NSCLC) and RET-mutant medullary thyroid carcinoma (MTC). The company plans to submit an NDA for pralsetinib pertaining to the NSCLC ..."

Published: Oct 14th, 2019 9:09 PM

FDA Awards $4.1 Billion In Funding For Rare Disease Research

"The grants will specifically go to research for medullary thyroid carcinoma and Duchenne muscular dystrophy, but these subsequent findings will likely ..."

Published: Oct 14th, 2019 8:22 PM

NextUp: Tmunity Therapeutics Is Pioneering Personalized Cancer Treatments

"Who: Tmunity Therapeutics was founded in 2015 by a team of experienced researchers, including Bruce Blazar, Bruce Levine, Yangbing Zhao, Jim ..."

Published: Oct 14th, 2019 5:56 PM

Eli Lilly Stock Gets 2 Pieces of Good News

"The company, however, has announced some promising data in recent months, including a 68% response rate for its experimental drug LOXO-292 ..."

Published: Oct 12th, 2019 5:22 AM

A pain in the neck

"Two other kinds of thyroid cancer - medullary and undifferentiated, which are extremely rare in that they make for less than one per cent of all thyroid ..."

Published: Oct 10th, 2019 7:37 PM

Lung Cancer Therapy Makes Major Advances

"At the World Conference on Lung Cancer, we saw results with LOXO-292 in a cohort of approximately 105 patients with RET-positive lung cancer."

Published: Oct 10th, 2019 5:00 PM

Precision oncology: Exciting clinical developments and complicated biology

"Drilon and colleagues presented results from the LIBRETTO clinical study of selpercatinib (LOXO-292, Loxo Oncology) in September at International ..."

Published: Oct 9th, 2019 5:11 AM

Coverage Initiated on US-Based Precision Therapy Developer

"... pointed out that H.C. Wainwright and key opinion leaders view the market opportunities for both avapritinib and pralsetinib to be "underappreciated."

Published: Oct 8th, 2019 8:22 PM

FDA awards two grants for natural history studies in rare diseases

"University of Texas MD Anderson Cancer Center (Houston, Texas), Elizabeth Grubbs, prospective study in medullary thyroid carcinoma, ..."

Published: Oct 7th, 2019 6:18 PM

Thermo Fisher Closes API Site Buyout, Fortifies Pharma Unit

"... identify certain non-small cell lung cancer (NSCLC) and thyroid cancer patients who may be treated with Lilly's investigational therapy, LOXO-292."

Published: Oct 4th, 2019 9:30 PM

At ESMO, more precision medicines show their worth

"... test group, people with RET-mutant medullary thyroid cancer who had previously received Cometriq (cabozantinib) and/or Caprelsa (vandetanib)."

Published: Oct 4th, 2019 8:32 PM

Precision Medicine for RET Fusion-Positive NSCLC

"Selpercatinib (LOXO-292), a RET kinase inhibitor, demonstrated antitumor activity in the lungs and brain and durable responses with acceptable ..."

Published: Oct 3rd, 2019 7:09 PM

Here's Why You Should Add Thermo Fisher to Your Portfolio

"... identify certain non-small cell lung cancer (NSCLC) and thyroid cancer patients, who may be treated with Lilly's investigational therapy, LOXO-292."

Published: Oct 2nd, 2019 11:56 PM

Eli Lilly and Company's (LLY) Management Presents at Lilly Oncology Update at ESMO 2019 ...

"... mutations occur in approximately 60% of sporadic medullary thyroid cancer, ... As you recall, data in RET fusion positive non-small cell lung cancer ..."

Published: Oct 2nd, 2019 3:52 PM

The Alliance for Regenerative Medicine Announces Election of 2020 ARM Officers, Executive ...

"WASHINGTON, D.C., Oct. 02, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- The Alliance for Regenerative Medicine (ARM), the international ..."

Published: Oct 2nd, 2019 6:27 AM

Selpercatinib in RET Fusion-Positive Thyroid Cancer

"Selpercatinib (previously known as LOXO-292) is an oral and selective investigational new agent that is being evaluated for the treatment of patients ..."

Published: Oct 1st, 2019 4:48 AM

Lilly's Loxo Bet Pays Off In Thyroid Cancer, A Second Indication For Selpercatinib

"The company reported positive Phase III response rate data weeks after strong results in lung cancer for the RET inhibitor also known as LOXO-292."

Published: Sep 30th, 2019 5:22 PM

Turning Point Therapeutics Announces FDA Clearance of Investigational New Drug Application for ...

"... of wildtype and mutated RET kinases as compared to proxy chemical compounds for investigational RET inhibitors, LOXO-292 and BLU-667."

Published: Sep 30th, 2019 3:47 PM

Eli Lilly Says Selpercatinib Shows 'Demonstrative Efficacy and Safety' in RET-Altered Thyroid ...

"In the RET-mutant medullary thyroid cancer population, selpercatinib achieved a 56% overall response rate (ORR) in patients who had prior treatment ..."

Published: Sep 30th, 2019 2:50 PM

Vantage Esmo 2019 roundup

"Thyroid results strengthen selpercatinib's case. 29 September. As selpercatinib confirms its activity in thyroid cancer, Lilly gears up to prove the Ret ..."

Published: Sep 30th, 2019 10:15 AM

Gemma Collins' weight loss jabs - the risks of the hunger fighting injections revealed

"However, it adds: "It is not known if Victoza will cause thyroid tumors or a type of thyroid cancer called medullary thyroid carcinoma (MTC) in people."."

Published: Sep 29th, 2019 11:56 PM

Selpercatinib Demonstrates Robust ORR in Thyroid Cancer

"Selpercatinib Demonstrates Robust ORR in Thyroid Cancer ... selpercatinib (formally LOXO-292) in patients with RET-mutant medullary thyroid cancer ..."

Published: Sep 29th, 2019 10:36 PM

Selpercatinib Shows Strong ORR in Thyroid Cancer, FDA Submission Expected

"The highly selective RET inhibitor selpercatinib (formally LOXO-292) demonstrated robust objective response rates (ORR) for patients with ..."

Published: Sep 29th, 2019 7:26 PM

ESMO: Lilly's RET drug shrinks more than half of rare thyroid cancers

"It's a different conversation with non-medullary thyroid cancers: "They are more molecularly diverse in a way that is helpful to our story. Today, BRAF ..."

Published: Sep 26th, 2019 12:18 AM

Eli Lilly Throws Hat In The Ring For Lung Cancer Space, Takes Targeted Treatment Approach

"Eli Lilly announced that it had achieved positive results from a phase 1/2 study using the drug selpercatinib to treat RET fusion-positive non-small cell ..."

Published: Sep 25th, 2019 9:18 PM

What to look out for at ESMO 2019

"At the start of the year, when Eli Lilly (NYSE: LLY) bought Loxo Oncology, the potential of its first-in-class oral RET inhibitor LOXO-292 was central to ..."

Published: Sep 24th, 2019 4:37 AM

Targeted Therapy For RET-Rearranged Non-Small Cell Lung Cancer: Clinical Development And ...

"Novel selective RET inhibitors like BLU-667, LOXO-292 and RXDX-105 have been recently investigated in early phase clinical trials showing ..."

Published: Sep 24th, 2019 12:30 AM

Lilly, Bayer's tumor-agnostic cancer drug gets European nod

"Another company, Blueprint Medicines, has a competing RET inhibitor in development, BLU-667 (pralsetinib). Analysts have remarked that the ..."

Published: Sep 22nd, 2019 6:18 PM

Thyroid Cancer Awareness Month

"And, unlike many other cancers, the mortality rate for thyroid cancer has ... Papillary (and variants), Follicular (including Hurthle Cell), Medullary and ..."

Published: Sep 20th, 2019 9:18 PM

Patients Who Use Natpara Say They are Suffering After Recall

"In this segment, we talk to Becky Buckman who took part in the clinical trials for Natpara and says the drug is a lifesaver. She is now part of a group of ..."

Published: Sep 20th, 2019 9:07 PM

Drugs in the Pipeline: Non-Small-Cell Lung Cancer

"Several promising drugs for the treatment of lung cancer have been ... papillary thyroid cancer (PTC), RET-mutant medullary thyroid cancer (MTC), ..."

Published: Sep 19th, 2019 2:56 PM

Thyroid Cancer: Knowing The Facts This Thyroid Cancer Awareness Month

"A small gland located at the base of the neck, the thyroid is part of our ... People with a family history of thyroid cancer, especially medullary thyroid ..."

Published: Sep 18th, 2019 11:56 PM

Selpercatinib Promising in RET Fusion-Positive NSCLC

"... platinum-based chemotherapy and an anti-PD-1 or anti-PD-L1 therapy; RET-mutant medullary thyroid cancer (MTC) who require systemic therapy, ..."

Published: Sep 18th, 2019 6:41 PM

It's really scary Recall of Natpara leaves patients in limbo"

"Natpara was recalled this month because tiny pieces of rubber from the injector were found in some vials of the drug, which could contaminate the ..."

Published: Sep 18th, 2019 11:23 AM

NorCal patients live in fear after parathyroid drug recall

"People suffering from a rare, but potentially deadly disease are now living in fear after their life-saving medication called Natpara was suddenly ..."

Published: Sep 17th, 2019 12:30 AM

How a Once-Weekly Injection Can Help Manage Type 2 Diabetes

"It is unknown whether BYDUREON BCise causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC) in humans, as the human ..."